P
rotocol I5T- MC-AACN(b)  
A
 Phase 3, Open-Label, Parallel -Group, 2-Arm Study to Investigate Amyloid Plaque Clearance 
with Donanemab Compared with Aducanumab-avwa in Participants with Early Symptomatic  
Alzheimer’s Disease  
N
CT05108922 
A
pproval Date: 17- May-2022 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_541417] (LY3002813), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commerciall y confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 a nd may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.  
Protocol Title:   
A Phase 3, Open-Label, Parallel -Group, 2-Arm Study to Investigate Amyloid Plaque Clearance  
with Donanemab  Compare d with Aducanumab -avwa in Participants with Early Symptomatic 
Alzheimer’s Disease  
Protocol Number: I5T-MC-AACN  
Amendment Number: b  
Compound: donanemab (LY3002813)  
Brief Title:  
A Study to Investigate Amyloid Plaque Clearance with Donanemab Compared with 
Aducanumab -avwa in Participants with Early Symptomatic Alzheimer’s Disease  
Study Phase: 3 
Acronym:  TRAILBLAZER -ALZ 4  
Sponsor Name: [CONTACT_11028]:  Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s)  
IND: 109157  
Document ID:  VV-CLIN -059456  
Approval Date: Protocol Amendment ( b) Electronically  Signed and  Approved  by [CONTACT_10937].   
  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705954] Information will be provided separately.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705955]-2021  
Original Protocol  17-Aug-2021  
Amendment b  
Overall Rationale for the Amendment:  
This amendment adds an MRI at Visit 10 due to a  recent label update to aducanumab -avwa . 
 
Section # and 
Name  [CONTACT_11029]  
1.3 Schedule of 
Activities  Added an MRI to Visit 10 . Align with label update to aducanumab -
avwa  
7.1.3  Amyloid -
Related Imaging 
Abnormalities 
(ARIA)  Clarif ied the timing of ARIA 
or donanemab  v aducanumab -
avwa .  Minor clarification.  
   
   
   
   
   
   
   
   
 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
4 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 7 
1.1. Synopsis  ................................ ................................ ................................ ............................ 7 
1.2. Schema  ................................ ................................ ................................ ............................ 12 
1.3. Schedule of Activ ities (SoA)  ................................ ................................ .......................... 13 
2. Introduction  ................................ ................................ ................................ ................... 23 
2.1. Study Rationale  ................................ ................................ ................................ ............... 23 
2.2. Backgro und ................................ ................................ ................................ ..................... 23 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 24 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......25 
4. Study Design  ................................ ................................ ................................ .................. 28 
4.1. Overall Design  ................................ ................................ ................................ ................ 28 
4.2. Scientifi c Rationale for Study Design  ................................ ................................ ............ 28 
4.3. Justification for Dose  ................................ ................................ ................................ ......29 
4.4. End of Study Definition  ................................ ................................ ................................ ..29 
5. Study Population  ................................ ................................ ................................ ........... 30 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ............ 30 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 31 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .32 
5.4. Screen Failures  ................................ ................................ ................................ ................ 33 
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention 
of a Participant  ................................ ................................ ................................ ................ 33 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 34 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 34 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 34 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 35 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 35 
6.5. Dose Modification  ................................ ................................ ................................ .......... 36 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 36 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...36 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....36 
6.8.1.  Medications for Alzheimer’s Disease  ................................ ................................ ............. 37 
6.8.2.  Medications for Infusion Reactions  ................................ ................................ ................ 37 
6.8.3.  Excluded Medications  ................................ ................................ ................................ .....37 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 38 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 38 
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_278779] ................................ ................................ .................. 38 
7.1.2.  QTc Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ .....39 
7.1.3.  Amyloid -Related Imaging Abnormalities (ARIA)  ................................ ......................... 39 
7.1.4.  Temporary Discontinuation  ................................ ................................ ............................ 40 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
5 7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_705956]  ................................ ................................ ................. 51 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 51 
8.5. Pharmac odynamics  ................................ ................................ ................................ ......... 51 
8.6. Genetics  ................................ ................................ ................................ .......................... 51 
8.6.1.  Apolipoprotein E Genotypi[INVESTIGATOR_007]  ................................ ................................ ......................... 51 
8.6.2.  Whole Blood Samples for Pharmacogenetic Research  ................................ ................... 51 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 52 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 52 
8.9. Health Economics  ................................ ................................ ................................ ........... 52 
9. Statistical Considerations  ................................ ................................ ............................. 53 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....53 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 53 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 54 
9.3.1.  General Considerations  ................................ ................................ ................................ ...54 
9.3.2.  Treatment Group Comparability  ................................ ................................ ..................... 55 
9.3.3.  Primary Analyses  ................................ ................................ ................................ ............ 56 
9.3.4.  Secondary Analyses  ................................ ................................ ................................ ........ 56 
9.3.5.  Other Safety Analyses ................................ ................................ ................................ .....57 
9.3.6.  Other Analyses  ................................ ................................ ................................ ................ 58 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 58 
9.5. Sample Size Determination  ................................ ................................ ............................ 58 
10. Supporting Documentation and Operational Considerations  ................................ ..60 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Consideration s ................................ ................................ ................................ ................ 60 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 60 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 60 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 61 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 61 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
6 10.1.5.  Committees Structure ................................ ................................ ................................ ......61 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 62 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..62 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 64 
10.1.9.  Study and Site Start and Closure  ................................ ................................ .................... 64 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 65 
10.1.11.  Investigator Information  ................................ ................................ ................................ .65 
10.1.12.  Sample Retention  ................................ ................................ ................................ ............ 65 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 66 
10.2.1.  Clinical Laboratory Tests for Hypersensitivity Events  ................................ ................... 67 
10.3.  Appe ndix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ [ADDRESS_705957] Complaints  ................................ ................................ ................... 72 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 72 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 74 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 75 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 76 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 76 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..76 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......77 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 78 
10.7.  Appendix 7: Flortaucipir F18 PET Imaging  ................................ ................................ ...80 
10.8.  Appendix 8:  Florbetapir F18 PET Imaging  ................................ ................................ ...82 
10.9.  Appendix 9:  CDR and MMSE  ................................ ................................ ....................... [ADDRESS_705958]  ................................ ................................ ................................ ................................ 83 
10.9.2.  MMSE  ................................ ................................ ................................ ............................. 83 
10.10.  Appendix 10: Abbreviations and Definitions  ................................ ................................ .84 
11. References  ................................ ................................ ................................ ...................... 90 
 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
7 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:   
A Phase 3, Open -Label, Parallel -Group, 2 -Arm Study to Investigate Amyloid Plaque Clearance 
with Donanemab Compared with Aducanumab -avwa in Participants with Early Symptomatic 
Alzheimer’s Disease  
Brief Title:   
A Study to Investigate Amyloid Plaque Clearance with Donanemab Compared with 
Aducanumab -avwa in Participants with Early Symptomatic Alzheimer’s Disease  
Rationale:  
Study I5T -MC-AACN (AACN) is a Phase 3, open -label, head -to-head study to evaluate the 
superio rity of donanemab to aducanumab in participants with Early Symptomatic AD. 
The amyloid hypothesis of AD postulates that the production and deposition of Aβ is an early 
and necessary event in the pathogenesis of AD (Selkoe 2000). Both donanemab and aducanum ab 
have previously demonstrated the ability to reduce brain amyloid plaque burden and potentially 
slow clinical decline  (Sevigny et al 2016 ; Mintun et al 2021; Aducanumab USPI, 2021 ). 
Recently, the FDA approved aducanumab , in the US, under accelerated appr oval for the 
treatment of AD based on its ability to reduce amyloid plaque burden  (Aducanumab USPI, 
2021) . The current study aims to evaluate the superiority of donanemab to aducanumab on 
amyloid plaque clearance  in participants with early symptomatic AD . 
Objectives, Endpoints, and Estimands:  
Objectives  Endpoints  
Co-Primary   
To assess the superiority of donanemab 
versus aducanumab on complete brain 
amyloid plaque clearance in participants with 
early symptomatic AD . Superiority of p ercentage of  participants  who 
reach complete amyloid plaque clearance on 
florbetapir F18 PET scan on donanemab 
versus aducanumab at  6 months . 
To assess the superiority of donanemab 
versus aducanumab on complete brain 
amyloid plaque clearance in the intermediate 
tau su bpopulation of participants with early 
symptomatic AD.  Superiority of percentage of participants who 
reach complete amyloid plaque clearance on 
florbetapir F18 PET scan in the intermediate 
tau subpopulation on donanemab versus 
aducanumab at 6 months.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
8 Key Secondary   
To assess the superiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction . Superiority of mean absolute change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan for donanemab 
versus aducanumab at : 
 6 months  
 12 months , and  
 18 months . 
To assess the superiority of donanemab 
versus aducanumab in time to reach complete 
amyloid plaque clearance . Time to reach complete amyloid plaque 
clearance on donanemab versus aducanumab . 
Other Secondary   
To assess the superiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction . Superiority of mean percent change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan for donanemab 
versus aducanumab at : 
 6 months  
 12 months , and  
 18 mont hs. 
To assess the non -inferiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction . Non-inferiority of mean absolute change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan at : 
 donanemab 6 months vs aducanumab 
12 months , and  
 donanemab 6 months vs aducanumab 
18 months . 
To assess the superiority of donanemab 
versus aducanumab on complete brain 
amyloid plaque clearance.  Superiority of percentage of participants who 
reach complete amyloid plaque clearance on 
florbetapir F18 PET scan on donanemab 
versus aducanumab at : 
 12 months , and  
 18 months . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
9 To assess the superiority of donanemab 
versus aducanumab on complete brain 
amyloid plaque clearance in the intermediate 
tau subpopulation.  Superiority of percentage of p articipants who 
reach complete amyloid plaque clearance on 
florbetapir F18 PET scan in the intermediate 
tau subpopulation on donanemab versus 
aducanumab at : 
 12 months , and  
 18 months . 
To assess the superiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction in the intermediate 
tau subpopulation . Superiority of mean absolute  change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan in the intermediate 
tau subpopulation for donanemab vs 
aducanumab at :  
 6 months  
 12 months , and  
 [ADDRESS_705959] safety 
assessments:  
 Spontaneously reported AEs  
 Clinical laboratory tests 
 MRI (ARIA and emergent radiological 
findings)  
 Serious hypersensitivity reactions  
 C-SSRS  
Abbreviations: AD = Alzheimer's disease ; AE = adverse event; ARIA = amyloid -related imaging abnormalities ; C-
SSRS = Columbia Suicide -Severity Rating Scale; MRI = magnetic resonance imaging; PET = positron emission 
tomography.  
NOTE: Other pre -specified, non -gated endpoints not listed will be detailed in the SAP.  
Overall Design  
Study I5T -MC-AACN (AACN) is a Phase 3, open -label, head -to-head study to evaluate the 
superiority of donanemab to aducanumab in participants with  early symptomatic  AD. 
Brief Summary:  
Study AACN is a multicenter, randomized, open -label, head -to-head, Phase 3 study of 
donanemab compared to aducanumab in participants with  early symptomatic  AD. 
Participants who meet entry criteria will be randomized in a 1:1 ratio to 1 of the following 
treatment groups:  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
10  donanemab: [ADDRESS_705960] 3 doses and then 1400 mg IV Q4W  
 aducanumab: Refer to PI/routine clinical practice  
The maximum total durat ion of study participation for each participant, including screening and 
the post -treatment follow -up periods, is up to 127 weeks:  
 Lead -In:  any time prior to complete screening  
 Complete Screening:  up to 7 weeks  
 Open -label study period :  76 weeks  
 Follow -Up:  up to 44 weeks  
The maximum duration of treatment is 72 weeks.  
Scheduled Reduction of Donanemab  
Participants randomized to donanemab  whose amyloid plaque reduction as measured by 
[CONTACT_389754] F18 PET scans at Visit 8 (Week 24) or Visit 15 (Week 5 2) meets criteria will stop 
donanemab infusions but continue all other assessments for the remaining duration of the open -
label  period  and short -term follow -up period . These dose  reduction rules are defined by [CONTACT_103].  
Participants randomized to aducan umab will continue monthly infusions throughout the open -
label period, regardless of amyloid plaque reduction on florbetapir F18 PET scans.  
Participant  randomization will be stratified by [CONTACT_541435] ε4 status  
(noncarrier/heterozygous/homozygous) . 
Number of Participant s: 
Approximately 200 participants will be randomly assigned  to study intervention.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
11 Intervention Groups and Duration:  
Intervention Name  [CONTACT_541467](s)  [ADDRESS_705961] 3 doses and 
then 1400 mg IV 
Q4Wa Refer to PI/routine 
clinical practice  
Route of 
Administration  IV infusion  IV infusion  
Use experimental  active -comparator  
Abbreviations: IV = intravenous; PI = package insert; Q4W = once every 4 weeks.  
a Participants randomized to donanemab  whose amyloid plaque reduction as measured by [CONTACT_389754] F18 PET scans 
at Visit 8 (Week 24) or Visit 15 (Week 52) meets criteria will stop donanemab infusions but continue all other 
assessments for the remaining duration of the ope n-label period  and short -term follow -up period.  These dose 
reduction rules are defined by [CONTACT_456].  
Data Monitoring Committee: Yes 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
12 1.2. Schema  
  
  
Abbreviations: IV = intravenous; mg = milligrams; Q4W = every 4 weeks.  
Note: V601 is optional. For participants who do not complete V601, procedures will be included in V1.  
Randomization occurs at V2.  
a Participants whose amyloid plaque reduction as measured by [CONTACT_389754] F18 PET scans at Vis it 8 (Week 24) or Visit 15 (Week 52) meets criteria will stop 
donanemab infusions but continue all other assessments for the remaining duration of the open -label period and short -term follow -up period . These dose 
reduction rules are defined by [CONTACT_456].  

CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
13 1.3. Schedule of Activities (SoA)  
Screening  
 LEAD -IN SCREENING  COMPLETE SCREENING  Notes  
Visit No.:  601*  1 V1 may be conducted over more than 1 
day. 
*V601 is optional. If the participant’s 
initial visit is V1, then perform all V601 
procedures in addition to V1 procedures.  
Day Relative to 
Randomization  Can be done any time prior to 
complete screening  -49 to -1  
Tolerance Interval for 
Visit (Days)  Can be done at any time  ≤49 before V2   
Entry and Administrative  
Abbreviated (or Full) 
Informed 
Consent  – participant  X  The Abbreviated Informed Consent 
grants consent only for procedures and 
assessments marked under V601.  
 
Full Informed Consent – 
participant   X Do not collect if Full Informed Consent 
was collected at V601.  
Full Informed Consent –
study partner X  Study partner(s) are not required to 
complete the abbreviated Informed 
Consent.  
Participant number assigned 
via IWRS  X   
Demographics  X   
Inclusion/exclusion review   X  
Physical/neurological 
examination  X As described in the Manual of 
Operations.  
Concomitant medications   X  
Preexisting conditions   X  
Assessments  
Height and weight   X  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
14  LEAD -IN SCREENING  COMPLETE SCREENING  Notes  
Visit No.:  601*  1 V1 may be conducted over more than 1 
day. 
*V601 is optional. If the participant’s 
initial visit is V1, then perform all V601 
procedures in addition to V1 procedures.  
Day Relative to 
Randomization  Can be done any time prior to 
complete screening  -49 to -1  
Tolerance Interval for 
Visit (Days)  Can be done at any time  ≤[ADDRESS_705962] any other 
screening procedures performed.   
Administer the MMSE prior to medical 
procedures that could be stressful to the 
participant (blood draws, etc.).   
CDR  X  Administer the CDR prior to medical 
procedures that could be stressful to the 
participant (blood draws, etc.).   
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
15  LEAD -IN SCREENING  COMPLETE SCREENING  Notes  
Visit No.:  601*  1 V1 may be conducted over more than 1 
day. 
*V601 is optional. If the participant’s 
initial visit is V1, then perform all V601 
procedures in addition to V1 procedures.  
Day Relative to 
Randomization  Can be done any time prior to 
complete screening  -49 to -1  
Tolerance Interval for 
Visit (Days)  Can be done at any time  ≤49 before V2   
Screening PET Scans and MRI  
Florbetapir F18 PET scan   
X The participant should meet all other 
non-imaging  eligibility criteria before 
the screening florbetapir F18 PET scan.  
Previous florbetapir F18 PET scans 
within 3 month s of randomization  may 
be acceptable. The acceptance of a 
historical scan is at the discretion of the 
sponsor.  
MRI   
X The participant should meet all other 
non-imaging eligibility criteria before 
the screening MRI.   
Abbreviations:  ApoE = apolipoprotein E;  CDR = Clinical Dementia Rating; C -SSRS = Columbia -Suicide Severity Rating Scale; ECG = electrocardiogram; 
IWRS = interactive web response system; MMSE = Mini -Mental State Exam; MRI = magnetic resonance imaging; PET = positron emission tomography; V = 
visit.  
 
  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705963] 
infusion  0 4 8 12 16 20 24 28 32 36  
Visit interval tolerance 
(days)   -7 to 
+10 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_705964] dose of study 
intervention.  
Randomization  X           
Brief 
Physical /Neurological  
Exam  X   X   X   X As described in the Manual of Operations . 
Any clinically significant changes from baseline on brief 
physical/neurological examinations should be noted on the AE CRF.  
Concomitant medications  X X X X X X X X X X  
AEs X X X X X X X X X X Any events that occur after signing the informed consent are 
considered AEs as defined in Section 10.3. 
C-SSRS 
screening/baseline  X            
C-SSRS since last 
assessment    X  X  X  X   
Administer study 
intervention  X X X X X X X  X X X See Section 6.1. 
Administration of study intervention (and treatment -related activities 
conducted in person) outside of the visit window is not a protocol 
deviation, unless 2 doses are administered with in <21 days of each 
other.  
The participant should be observed for a minimum of 30  minutes 
following the end of each infusion.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705965] 
infusion  0 4 8 12 16 20 24 28 32 36  
Visit interval tolerance 
(days)   -7 to 
+10 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_705966] 
5 minutes.  
Vital signs are measured prior to and within 30  minutes after infusion 
for clinical management, and not recorded in the CRF.  
Weight (for aducanumab 
participants only)  X X X X X X X X X X Weight is measured prior to dosing with aducanumab only and is not 
recorded in the CRF.   
MRI    
   X  X    X   X    MRI at V3 is to be performed and reviewed prior to V3 infusion and 
may occur no sooner than [ADDRESS_705967] 14 days after infusion at V9 is 
administered, and may occur outside of the visit windows.  
 
Unscheduled MRIs may be performed at the discretion of 
investigator, for example, if titra tion is delayed due to temporary 
suspension of infusions.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705968] 
infusion  0 4 8 12 16 20 24 28 32 36  
Visit interval tolerance 
(days)   -7 to 
+10 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_705969] +/ - 3 months from 
randomization to obtain flortaucipir  results (either from pre -existing 
scan or new scan) . 
PET scans must be performed ≥[ADDRESS_705970] be performed ≥16 hours apart from each other.  
Laboratory Tests and 
Sample Collections  In the event that study intervention is delayed, all laboratory collections should occur on the same day as study interventio n 
infusion – and should be collected prior to infusion.  
Hematology and  clinical 
chemistry        X    Collect prior to infusion.  
PK sample             X      Collect prior to infusion. Predose collections may be collected from 
the IV site prior to the infusion.  
 
Immunogenicity (ADA) 
samples  X          X      Collect prior to infusion.  
Stored Samples             
Genetics sample  X                  Collect prior to infusion.  
Exploratory biomarker 
samples  X            X      Collect prior to infusion.  
Abbreviations:  ADA = anti -drug antibody; AEs = adverse events; CRF = case reporting form; C-SSRS = Columbia -Suicide Severity Rating Scale; MRI = 
magnetic resonance imaging; PET = positron emission tomography; PK =  pharmacokinetic ; V = visit.  
 
  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
19 Visits 12 through 21 and Follow -Up 
 
 Open -Label Treatment  Short-term 
Follow -up Comments  
Visit Number  12 13 14 15 16 17 18 19 20 21 ET 801-804^ ^Visit [ADDRESS_705971] 
infusion  40 44 48 52 56 60 64 68 72 76 - 84-120  
Visit interval tolerance 
(days)  ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 - ±14  
Entry and Administrative   
Brief 
Physical /Neurological  
Exam     X   X   X X X As described in the Manual of 
Operations .  
Any clinically significant changes 
from baseline on brief 
physical/neurological examinations 
should be noted on the AE CRF.  
Concomitant medications  X X X X X X X X X X X X  
AEs X X X X X X X X X X X X Any events that occur after signing 
the informed consent are 
considered AEs as defined in 
Section  10.3. 
C-SSRS since last 
assessment  X  X  X  X  X  X X  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
20  Open -Label Treatment  Short-term 
Follow -up Comments  
Visit Number  12 13 14 15 16 17 18 19 20 21 ET 801-804^ ^Visit [ADDRESS_705972] 
infusion  40 44 48 52 56 60 64 68 72 76 - 84-120  
Visit interval tolerance 
(days)  ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 - ±14  
Administer study 
intervention  X X X X X X X X  X   
 See Section 6.1. 
Administration of study 
intervention (and treatment -related 
activities conducted in person) 
outside of the visi t window is not a 
protocol deviation, unless 2 doses 
are administered within <[ADDRESS_705973] 5  minutes.  
Vital signs are measured prior to 
and within 30  minutes after 
infusion for clinical management, 
and not recorded in th e CRF.  
Weight (for aducanumab 
participants only)  X X X X X X X X  X    Weight is measured prior to dosing 
with aducanumab only and is not 
recorded in the CRF.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
21  Open -Label Treatment  Short-term 
Follow -up Comments  
Visit Number  12 13 14 15 16 17 18 19 20 21 ET 801-804^ ^Visit [ADDRESS_705974] 
infusion  40 44 48 52 56 60 64 68 72 76 - 84-120  
Visit interval tolerance 
(days)  ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 - ±[ADDRESS_705975] prior to infusion . Predose 
collections may be collected from 
the IV site prior to the infusion.  
Immunogenicity (ADA) 
samples       X          X X X Collect prior to infusion.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
22  Open -Label Treatment  Short-term 
Follow -up Comments  
Visit Number  12 13 14 15 16 17 18 19 20 21 ET 801-804^ ^Visit [ADDRESS_705976] 
infusion  40 44 48 52 56 60 64 68 72 76 - 84-120  
Visit interval tolerance 
(days)  ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 - ±[ADDRESS_705977] prior to infusion.  
Abbreviations:  ADA = anti -drug antibody; AEs = adverse events; CRF = electronic case reporting form; C-SSRS = Columbia -Suicide Severity Rating Scale; ET 
= early termination; MRI = magnetic resonance imaging; PET = positron emission tomography; PK =  pharmacokinetic ; V = visit.  
 
 
 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705978] amino acid of 
amyloid beta (N3pG Aβ) epi[INVESTIGATOR_541418]. I t is being studied 
for the treatment of AD. The mechanism of action of donanemab antibody is to target  and 
remove deposited amyloid plaque, a key pathological hallmark of AD, via microglial -mediated 
clearance.  
Aducanumab is a human anti -Aβ monoclonal antib ody that selectively targets aggregated forms 
of Aβ, including soluble oligomers and insoluble fibrils (Ferrero et al 2016). It was recently 
approved, in the US, under accelerated approval for the treatment of AD (Aducanumab USPI, 
2021).  
2.1. Study Rationale  
Study I5T -MC-AACN (AACN) is a Phase 3, open -label, head -to-head study to evaluate the 
superiority of donanemab to aducanumab in reaching  amyloid plaque clearance  in participants 
with early symptomatic AD. 
This strategy is based on the amylo id hypothesis of AD, which postulates that the production and 
deposition of Aβ is an early and necessary event in the pathogenesis of AD (Selkoe 2000). 
Clinical data supporting this hypothesis comes from the observation that parenchymal Aβ levels 
are eleva ted prior to the manifestation of AD symptoms , and further supported by [CONTACT_541436] Aβ and genetic variants that protect against Aβ production 
(Jonsson et al. 2012; Fleisher et al. 2015). Furthermore, early in the disease, the presence of brain 
amyloid appears to incr ease the risk of conversion from MCI to AD dementia (Doraiswamy et al. 
2012). These data suggest that removal of deposited amyloid and clearance of Aβ can result in 
the slowing of AD progression.  Both donane mab and aducanumab have previously demonst rated 
the ability to reduce brain amyloid plaque burden  and potentially slow clinical decline  (Sevigny 
et al 2016 ; Mintun et al 2021; Aducanumab USPI, 2021 ). Recently, the FDA approved 
aduc anumab for clinical use  based on its ability to reduce amyloid plaq ue burden  (Aducanumab 
USPI, 2021) . The current study aims to evaluate the  superiority of donanemab to aducanumab in 
reaching amyloid plaque clearance . 
2.2. Background  
Alzheimer’s disease is an age -related neurodegenerative disorder characterized by [CONTACT_541437]. The amyloid 
hypothesis of AD postulates that the accumulation of Aβ is an early and necessary event in the 
pathogenesis of AD. This hypothesis  suggests that interventions  that slow the accumulation of 
Aβ plaque in the brain or increase clearance of Aβ may be able to slow the progression of the 
AD clinical syndrome. Another  hallmark neuropathological lesion of AD is comprised of 
intraneuronal, ne urofibrillary tangles consisting of tau proteins, which spread through the brain 
and mark disease progression (Braak and Braak 1996). The relationship between these 2 
pathologies is still unclear, although the presence of both is necessary for the diagnosi s of 
definite AD.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
24 Converging evidence from both genetic at -risk and age at -risk cohorts suggests that the 
pathophysiological process of AD begins well more than a decade before the clinical stage now 
recognized as AD dementia, and that ne urodegeneration is already apparent on MRI by [CONTACT_541438]  (Jack et al 2010) . Like many disorders, AD occurs on a continuum from asymptomatic 
(preclinical) to MCI, and then to dementia in mild, moderate, and severe stages. Recent clinical 
trial results  in mild -to-moderate AD dementia, as well as evidence from transgenic animal 
experiments, suggest that treating AD during the earlier stages could have the greatest potential 
benefit on the disease and inhibiting progression, particularly when considering therapi[INVESTIGATOR_541419] Aβ reduction (Doody et al. 2014; Fleisher et al. 2015; Siemers et al. 2016).  
2.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of dona nemab  may be found in the IB, Participant Information Leaflet, 
Package Insert, or Development Safety Update Report or Summary of Product Characteristics . 
More detailed information about the known and expected benefits and risks and reasonably 
expected adve rse events of aducanumab may be found in the Participant Information Leaflet , 
Package Insert , or Summary of Product Characteristics . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
25 3. Objectives, Endpoints, and Estimands  
Objectives  Endpoints  
Co-Primary   
To assess the superiority of donanemab 
versus aducanumab on complete brain 
amyloid plaque clearance in participants with 
early symptomatic AD.  Superiority of percentage of participants who 
reach complete amyloid plaque clearance on 
florbetapir F18 PET scan on donanemab 
versus aducanumab at 6 months.  
To assess the superiority of donanemab 
versus aducanumab on complete brain 
amyloid plaque clearance in the intermediate 
tau subpopulation of participants with early 
symptomatic AD.  Superiority of percentage of participants who 
reach complete amyloid plaque  clearance on 
florbetapir F18 PET scan in the intermediate 
tau subpopulation on donanemab versus 
aducanumab at 6 months.  
Key Secondary   
To assess the superiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction.  Superiority of mean absolute change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan for donanemab 
versus aducanumab at:  
 6 months  
 12 months , and  
 18 months . 
To assess the superiority of donanemab 
versus aducanumab in time to reach complete 
amyloid plaque  clearance.  Time to reach complete amyloid plaque 
clearance on donanemab versus aducanumab.  
Other Secondary   
To assess the superiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction . Superiority of mean percent change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan for donanemab 
versus aducanumab at:  
 6 months  
 12 months , and  
 18 months . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
26 Objectives  Endpoints  
To assess the non -inferiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction . Non-inferiority of mean absolute change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan at:  
 donanemab 6 months vs aducanumab 
12 months , and  
 donanemab 6 months vs aducanumab 
18 months . 
To assess the superiority of donanemab 
versus aducanumab on complete bra in 
amyloid plaque clearance.  Superiority of percentage of participants who 
reach complete amyloid plaque clearance on 
florbetapir F18 PET scan on donanemab 
versus aducanumab at:  
 12 months , and  
 18 months . 
To assess the superiority of donanemab 
versus aducanumab on complete brain 
amyloid plaque clearance in the intermediate 
tau subpopulation.  Superiority of percentage of participants who 
reach complete amyloid plaque clearance on 
florbetapir F18 PET scan in the intermediate 
tau subpopulation on donanemab versus 
aducanumab at:  
 12 months , and  
 18 months . 
To assess the superiority of donanemab 
versus aducanumab on degree of brain 
amyloid plaque reduction in the intermediate 
tau subpopulation . Superiority of mea n absolute change from 
baseline in brain amyloid plaque on 
florbetapir F18 PET scan in the intermediate 
tau subpopulation for donanemab vs 
aducanumab at :  
 6 months  
 12 months , and  
 18 months . 
To assess the superiority of donanemab 
versus aducanumab on degre e of brain 
amyloid plaque reduction . Superiority of change from baseline in brain 
amyloid plaque reduction on florbetapir F18 
PET scan for donanemab 6 months vs 
aducanumab 12 months . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705979] safety 
assessments:  
 Spontaneously reported AEs  
 Clinical laboratory tests  
 MRI (ARIA and emergent radiological 
findings)  
 Serious hypersensitivity reactions  
 C-SSRS  
Abbreviations: AD = Alzheimer's disease; AE = adverse event; ARIA  = amyloid -related imaging abnormalities; C -
SSRS = Columbia Suicide -Severity Rating Scale; PET = positron emission tomography ; SAP = Statistical 
Analysis Plan . 
NOTE: Other pre -specified, non -gated endpoints not listed will be detailed in the SAP.  
Estimands  
Estimands are described in the SAP.  
 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
28 4. Study Design  
4.1. Overall Design  
Study AACN is a multicenter, randomized, open -label, head -to-head, Phase 3 study of 
donanemab compared to aducanumab in participants with early symptomatic AD. 
Participants who meet entry cr iteria will be randomized in a 1:1 ratio to 1 of the following 
treatment groups:  
 donanemab:  [ADDRESS_705980] 3 doses and then 1400 mg IV Q4W  
 aducanumab:  refer to PI/routine clinical practice  
The maximum total duration of study participation for ea ch participant, including screening and 
the post -treatment follow -up periods, is up to 127 weeks:  
 Lead -In:  any time prior to complete screening  
 Complete Screening:  up to 7 weeks  
 Open -label study period :  76 weeks  
 Follow -Up:  up to 44 weeks  
The maximum du ration of treatment is 72 weeks.  
Scheduled Reduction of Donanemab  
Participants randomized to donanemab whose amyloid plaque reduction as measured by 
[CONTACT_389754] F18 PET scans at Visit 8 (Week 24) or Visit 15 (Week 52) meets criteria will stop 
donanemab infusions but continue all other assessments for the remaining duration of the open -
label period  and short -term follow -up period . These dose reduction rules are defined by [CONTACT_103].  
Participants randomized to aducanumab will continue monthly infusions t hroughout the open -
label period, regardless of amyloid plaque reduction on florbetapir F18 PET scans.   
Change in amyloid burden (as assessed with florbetapir F18 PET by [CONTACT_541439]) will be compared in donanemab and aducanumab -treated participants.  
Participant  randomization will be stratified by [CONTACT_541440] ε4 status  
(noncarrier/heterozygous/homozygous) . 
4.2. Scientific Rationale for Study Design  
Study AACN is a Phase 3, open -label, head -to-head study to evalua te the superiority of 
donanemab to aducanumab in reaching amyloid plaque clearance in participants with early 
symptomatic AD.  
Amyloid plaque is a known hallmark pathology of AD, and is hypothesized to contribute to the 
cognitive and functional decline in people with AD. Therefore, it is hypothesized that the 
removal of amyloid by [CONTACT_541441].  
The study includes a screening visit, which can last up to [ADDRESS_705981] florbetapir  F18 PET imaging results in order to be randomized to donanemab or 
aducanumab . The duration of the open -label treatment  period of the study is 76 weeks and 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
29 includes up to 72 weeks of treatment with primary endpoint measure at 6 months , to assess the 
superiority  of donanemab  versus aducanumab  in reaching amyloid plaque clearance . 
In addition to AE reporting, safety measures such as laboratory assessments, MRI assessments  
(ARIA and emergent radiological findings) , serious hypersensitivity reactions, and assessments 
of suicidal ideation and behavior are included to facilitate a comprehensive safety evaluation.  
4.3. Justification for Dose  
Decreased p articipant  burden with a Q4W dosing schedule compared with a Q2W dosing 
schedule and comparable safety (see IB), [ADDRESS_705982] scheduled procedure shown in the SoA . 
 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
30 5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Participants ar e eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be 50 to 85 years of age inclusive, at the time of signing the informed 
consent.  
Type of Participant and Disease Characteristics  
2. Gradual and progressive change in memory function reported by [CONTACT_541442] ≥6 months.  
3. Meet florbetapir F18 PET scan criteria .  
4. A Clinical Dementia Rating (CDR) -Global Score of 0.5  or 1. 
5. An MMSE score between 2 0 and 30 (inclusive) . 
6. Must consent to apolipoprotein E (ApoE) genotypi[INVESTIGATOR_007] . 
7. Have a study partner who will provide written informed consent to participate, is in 
frequent contact [CONTACT_6635] (defined as at least 10 hours per week), and will 
accompany the participant to study visits or be  available by [CONTACT_389769].  
A second study partner may serve as backup. The study partner(s) is/are required to 
accompany the participant  for signing consent. One study partner is requested to be 
present on all days the C -SSRS is administe red and must be present at screening for the 
completion of the CDR. Other v isits must have a study partner available by [CONTACT_541443] a visit for the following assessments:  
 AEs and concomitant medications  
 Relevant portions of  the C -SSRS  
If a study partner must withdraw from study participation, a replacement may be allowed 
at the investigator’s discretion. The replacement will need to sign a separate informed 
consent on the first visit that he or she accompanies the participan t. 
8. Have adequate literacy, vision, and hearing for neuropsychological testing in the opi[INVESTIGATOR_541420].  
9. Are reliable and willing to make themselves available for the duration of the study and 
are willing to follow study p rocedures.  
Sex and Contraceptive/Barrier Requirements  
10.  Males and females will be eligible for this study.  
a. Contraceptive use by [CONTACT_288941].  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
31 b. Female participants . 
a. Women not of childbearing potential  (defined in Appendix 4, Section 10.4) 
may participate . 
Informed Consent  
11. Capable of giving signed informed consent as described in Appendix 1, which includes 
compliance with the requirements and restrictions listed in the ICF and in this protocol.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
12. Significant neurological disease affecting the central nervous system (other than AD ), 
that may affect cognition or ability to complete the study, including but not limited to, 
other dementias, serious infection of the brain, Parkinson’s disease, multiple concussions, 
history of transient ischemic attack or stroke, or epi[INVESTIGATOR_541421] (except 
febrile childhood seizures).  
13. Current serious or unstable medical  illnesses including cardiovascular, hepatic, renal, 
gastroenterologic, respi[INVESTIGATOR_696], endocrinologic, psychiatric  (including actively suicidal or 
deemed at risk of suicide , or current alcohol o r substance abuse) , immunologic, 
infectious , or hematologic disease and other conditions that, in the investigator’s opi[INVESTIGATOR_1649], 
could interfere with the analyses in this study; or has a life expectancy of approximately 
≤24 months . 
14. History of clinically significant multiple or severe drug allergies , or severe posttreatment 
hypersensitivity reactions (including but not limited to erythema multiforme major, linear 
immunoglobulin A dermatosis, toxic epi[INVESTIGATOR_194], and/or exfoliative dermatitis).  
15.  History of bleeding disorder  or use of medications with platelet anti -aggregant or anti -
coagulant properties (unless aspi[INVESTIGATOR_9601] ≤325 mg daily) . 
Imaging, Electrocardiograms, Laboratory Tests, and Physical Examination  
16. Have any clinically important abnormality a t screening , as determined by [CONTACT_1275],  on physical or neurological examination, ECG, MRI , or clinical laboratory 
test results that could be detrimental to the participant , compromise  study integrity, or 
show evidence of other etiologies for dement ia. 
17. Have any contraindications for MRI, including claustrophobia or the presence of 
contraindicated metal (ferromagnetic) implants/cardiac pacemaker.  
18. Have a centrally read MRI demonstrating presence of ARIA -E, >4 cerebral 
microhemorrhages, more than 1 area  of superficial siderosis, any macrohemorrhage or 
severe white matter disease at screening.  
19. Contraindications to having a PET scan . 
20. Sensitivity to florbetapir F18 or flortaucipir F18.  
21. Poor venous access.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
32 22. Present or planned exposure to ionizing radiation that, in combination with the planned 
administration of study PET ligands, would result in a cumulative exposure that exceeds 
local recommended exposure limits.  
23. ALT ≥2.5X ULN of the performing laboratory, AST ≥2.5X ULN, TBL ≥1.5X ULN, or 
ALP ≥2X ULN at scr eening.  
Note:  Participants with TBL ≥1.5X ULN are not excluded if they meet all of the 
following criteria for Gilbert’s syndrome:  
 Bilirubin is predominately indirect (unconjugated) at screening (direct bilirubin 
within normal limits).  
 Absence of liver disease.  
 ALT, AST, and ALP ≤1X ULN at screening.  
 Hemoglobin is not significantly decreased at screening.  
Prior/Concomitant Therapy  
24. Have known allergies to donanemab  or aducanumab , related compounds, or any 
components of the formulation.  
25. Have had prior or c urrent treatment with donanemab or aducanumab . 
Prior/Concurrent Clinical Study Experience  
26. Prior or current p articipation in any active or passive  immunotherapy study targeting Aβ, 
unless documentation of receipt of placebo.  
27. Are currently enrolled in any other interventional clinical trial involving a study 
intervention or any other type of medical research judged not to be scientifically or 
medically compatible with this study.  
28. Have participated, within the last 30 days, in a ny clinical trial involving a study 
intervention. Participation in observational studies may be permitted upon review of the 
observational study protocol and approval by [CONTACT_456].  
Other Exclusions  
29. Are study personnel directly involved with the execution of this study, and/or their 
immediate families. Immediate family is defined as a spouse, parent, child, or sibling, 
whether biological or legally adopted.  
30. Are Lilly employees or are employees of TPOs directly involved in the study which requires 
exclusion of their employees, or have s tudy partners who are Lilly employees or are 
employees of TPOs involved in a study which requires exclusion of their employees.  
5.3. Lifestyle Considerations  
Participant s should refrain from donating blood or blood products from the time of th eir 
screening visit until [ADDRESS_705983] dose of study intervention.  
Participant s should avoid excessive use of alcohol from the screening visit until the study ends. 
Excessive alcohol consumption is defined for men as consum ing an average of more than 3 
drinks per day, or more than 21 drinks per week. For women, excessive use of alcohol is defined 
as consuming an average of more than 2 drinks per day, or more than 14 drinks per week.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
33 5.4. Screen Failures  
A screen failure occurs when a participant who consents to participate in the clinical study is not 
subsequently enrolled in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants t o meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any SAE.  
Individuals w ho do not meet the criteria for participation in this study (screen failure) may not  be 
rescreened .   
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention 
of a Participant  
Not applicable.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
34 6. Study Intervention(s) and  Concomitant Therapy  
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to/used by a study participant 
according to the study protocol.  
6.1. Study Int ervention(s) Administered  
Intervention Name  [CONTACT_541467](s)  [ADDRESS_705984] 3 doses and 
then 1400 mg IV 
Q4Wa refer to PI/routine 
clinical practice  
Route of 
Administration  IV infusion  IV infusion  
Use experimental  active -comparator  
Abbreviations: IV = intravenous; PET = positron emission tomography;  PI = package insert; Q4W = once every 4 
weeks.  
a Participants randomized to donanemab  whose amyloid plaque reduction as measured by [CONTACT_389754] F18 PET scans 
at Visit 8  (Week 24) or Visit 15 (Week 52) meets criteria will stop donanemab infusions but continue all other 
assessments for the remaining duration of the open -label period  and short -term follow -up period.  These dose 
reduction rules are defined by [CONTACT_456].  
Donanemab  is administered by [CONTACT_12781] a minimum of [ADDRESS_705985] not be administered at a dosing 
interval of <21 days at any time in the study.  
See Section [IP_ADDRESS]  for infusion -related reactions.  
For aducanumab, it is expected that the investigator review appropriate product label/institutional 
guidelines for confirmation dosing (i.e., need for pre -medic ation, dose, schedule, toxicity 
management and dose modifications).  
Resuscitation equipment and rescue medications must be available wherever study intervention 
is administered.  
6.2. Preparation, Handling, Storage, and Accountability  
1. The investigator or designee must confirm appropriate storage conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
2. Only participants enr olled in the study may receive study intervention. Only authorized 
study personnel may supply, prepare, or administer study intervention. All study 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705986] be stored in a secure, environmentally controlled, and monitored 
(manual or automated) are a in accordance with the labeled storage conditions with access 
limited to the investigator and authorized study personnel.  
3. The investigator or authorized study personnel are responsible for study intervention 
accountability, reconciliation, and record mai ntenance (i.e., receipt, reconciliation, and 
final disposition records).  
4. Further guidance and information for the final disposition of unused study interventions 
are provided in the Pharmacy Manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is an open -label study in which participants will be randomized in a 1:1 ratio to 
donanemab:aducanumab.  
For between -group comparability, participant randomization will be stratified by [CONTACT_541444] ε4 status (noncarrier/heterozygous/homozygous ). Any further stratification variables 
will be stated in the  SAP. Assignment to treatment groups will be determined by a computer -
generated random  sequence using an IWRS. Randomization into 1 stratum may be discontinued 
or overenrolled at the discretion of the sponsor  to manage between -group comparability . 
All participants will be centrally assigned to randomized study intervention using an IWRS. 
Before the study is initiated, the log in information & directions for the IWRS will be provided to 
each site.  
In order to maintain the scientific integrity of this trial, access to certain aspects of the study data 
will be strictly control led prior to the potential interim analysis and testing of the primary and 
key secondary objectives . Access to the EDC system will be limited to those who require this 
information for their role and all access will be documented.  
For t he primary efficacy analysis  database, that is, the database to which study statisticians ( Lilly 
and/or its designee) have acc ess, measurements from post-baseline florbetapir F18 PET scans 
will be scrambled or masked  to preclude the ability to conduct the primary efficacy analysis . 
Scrambled or masked florbetapir F18 PET measurements  will be used in the reporting database 
until the interim analysis or the [ADDRESS_705987] treatment assignments.  
Further details are included in the study blinding plan.  
6.4. Study Intervention Compliance  
Study intervention will be administered under medical supervision by [CONTACT_170270]. The dose of study intervention and study participant identification will be confirmed 
prior to the time of dosing. The date and time of each dose administere d will be recorded in the 
source documents and in the CRF.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
36 Any infusion at which 75% or more of the infusion solution is given will be considered a 
complete infusion. If a participant attends a visit but does not receive a complete infusion (for 
example, d ue to technical complications), every effort should be made to complete the infusion 
within 24 hours of preparation. If less than 75% of the infusion solution is given, this must be 
recorded as an incomplete infusion on the CRF.  
Missed infusions should be recorded on the CRF. If at any time it is discovered that the 
participant has not completed proper dosing during the titration phase, the sponsor should be 
contact[CONTACT_541445] a proper 
titrat ion phase, if needed.  
6.5. Dose Modification  
Dose modification of donanemab  is not permitted in this study  except for participants whose 
amyloid plaque reduction meet s criteria , as described in Section 4.1, and some instances of 
ARIA; if ARIA occurs during the titration period (that is, before the fourth infusion of 
donanemab), dose modification can be considered at the discretion of the investigator or 
designee as described in the Manual of Operations. If an ARIA -E and/or symptomatic ARIA -H 
event occurs, additional data should be provided to the sponsor in the ARIA  Related Events  
CRF.   
Investigators should consult the aducanumab appropriate product label/institutional guidelines 
toxicity management and dose modifications.  
6.6. Continued Access to Study Intervention after the End of the Study  
Not applicable.  
6.7. Treatment of Overdose  
In the event of an overdose, the investigator or treating physic ian should:  
1. Contact [CONTACT_10990].  
2. Evaluate the participant to determine, in consultation with the medical monitor, whether 
study intervention should be interrupted or whether the dose should be reduced.  
3. Closely monitor the participant fo r any AE/SAE.  
4. Obtain a plasma sample for analysis of study intervention if requested by [CONTACT_35011] (determined on a case -by-case basis).  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_78256].  
6.8. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time  of enrollment or receives 
during the study must be recorded along with  
 reason for use  
 dates of administration including start and end dates , and 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
37  dosage information including dose and frequency . 
The medical monitor should be contact[CONTACT_541446].  
6.8.1.  Medications for Alzheimer’s Disease  
Use of approved or standard of care symptomatic treatments for AD is permitted during the  
study . When medically indicated, initiation, increase , or discontinuation of symptom atic 
treatments for AD is permitted.  
Disease -modifying prescription medications are not allowed at any time during the study.  
Nonmedication treatments for AD, such as behavioral management, are  permitted.  
6.8.2.  Medications for Infusion Reactions  
If an infusion reaction occurs, medications managing the reaction may be administered at the 
discretion of the investigator or designee, according to local practice guidelines. If the need for 
concomitant medication arises, in clusion or continuation of the participant may be at the 
discretion of the investigator  or designee. Concomitant therapy administered to treat an infusion 
reaction or as premedication for infusions should be documented in addition to completion of the 
Hype rsensitivity, Anaphylactic, and Infusion -Related Reactions CRF.  
6.8.3.  Excluded Medications  
IgG therapy (also known as gamma globulin or IVIG) is not allowed during the study.  Use of 
medications with platelet anti -aggregant or anti -coagulant properties (unless as pi[INVESTIGATOR_9601] ≤325 mg 
daily) are not allowed during the study.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
38 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1.  
7.1. Disconti nuation of Study Intervention  
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention. If study intervention is permanently discontinued, the participant should remain in 
the study to be evaluated  for safety and biomarker collection . See the SoA for data to be 
collected at the time of discontinuation of study intervention and follow -up and for any further 
evaluations that need to be completed.  
A participant should be permanently discontinued from s tudy intervention if  
 the participant becomes pregnant during the study  
 by [CONTACT_541447]’s designee (for example, legal guardian)  
 based on a specific AE profile, the Medical Monitor, or the study sponsor 
physician/scientist, in d iscussions with the Principal Investigator  
 incorrect enrollment  
 severe noncompliance to the study protocol in the judgment of the investigator  
 systemic hypersensitivity reaction suspi[INVESTIGATOR_541422]  
 participant requires an excluded therapeutic agent  
 based on investigator clinical judgment  
 participants answered ‘yes’ to Question 4 or 5 on the ‘Suicidal Ideation’ portion of the 
C-SSRS, or  
 participants answered ‘yes’ to any of the suicide -related behaviors on the Suicidal 
Behav ior portion of the C -SSRS.  
o a psychiatrist or appropriately trained professional may assist in the decision to 
discontinue the participant for C -SSRS responses.  
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_541423] a hepatic event or liver test 
abnormality should have additional hepatic safety data collected via  the CRF . 
Discontinuation of the study intervention  for abnormal liver tests  should be  considered by [CONTACT_541448] a participant meets 1 of the following conditions after consultation with the 
sponsor -designated medical monitor:  
 ALT or AST >8X ULN   
 ALT or AST >5X ULN for more than 2 weeks   
 ALT or AST >3X ULN and TBL >2X ULN or INR >1.5    
 ALT or AST >3X ULN with  the appearance of fatigue, nausea, vomiting, right upper -
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)   
 ALP >3X ULN   
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
39  ALP >2.5X ULN and TBL >2X ULN   
 ALP >2.5X ULN with the appearance of fatigue, nausea, vomiting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)   
7.1.2.  QTc Stoppi[INVESTIGATOR_42224] a clinically significant finding is identified (including, but not limited to changes from baseline 
in QT interval corrected using  QTcF after enrollment, the inves tigator or qualified designee will 
determine if the participant can continue in the study and if any change in participant 
management is needed. This review of the ECG printed at the time of collection must be 
documented. Any new clinically relevant findin g should be reported as an AE.  
7.1.3.  Amyloid -Related Imaging Abnormalities (ARIA)  
The development of ARIA -E and/or ARIA -H (microhemorrhages and/or cSS) are expected 
events and occur more commonly on treatment with donanemab  and aducanumab . 
While most cases of ARIA -E are asymptomatic, serious cases have been reported. Available data 
for donanemab suggest serious cases are most likely to occur early in dosing, after the first, 
second, or third infusion.  For aducanumab, enhanced clinical vigila nce for ARIA is 
recommended during the first 8 doses of treatment, particularly during titration.  
ARIA -E 
For asymptomatic mild -to-moderate ARIA -E, study intervention may be continued and 
participants may be monitored with unscheduled MRIs at the investigator’s discretion.  
If a participant develops ARIA -E to an extent deemed clinically significant by [CONTACT_170270], such as symptomatic ARIA -E or severe ARIA -E on imaging, then the investigator or 
designee may consider withholding study  intervention  (see Manual of Operations for temporary 
discontinuation guidance) . The participant should be monitored for improvement by [CONTACT_9268](s)  
(fluid attenuation inversion recovery and T2* gradient -recall echo). Symptoms should be 
monitored in participants  with symptomatic ARIA -E. Upon resolution of ARIA -E on imaging 
and resolution of associated symptoms, reinitiating study intervention can be considered by [CONTACT_42038].  If resolution  is not observed, participants should be permanently 
disco ntinued from study intervention, but continue other study activities  (see Manual of 
Operations for permanent discontinuation guidance) . 
If ARIA -E occurs during the titration period, dose modifications may be considered (see Manual 
of Operations).  
In the ev ent of a finding of ARIA -E on MRI, the investigator is to complete the ARIA Related 
Events CRF regarding the presence or absence of symptoms related to the ARIA -E, and ARIA -E 
should be reported as an AE in the AE CRF. Information regarding symptoms attribu ted to the 
ARIA -E event should be entered in the ARIA Related Events CRF and should not be reported as 
AEs.  
ARIA -H 
See Manual of Operations for temporary and permanent discontinuation guidance. For new or 
increased number or severity of asymptomatic ARIA -H, in some circumstances,  study 
intervention may be  temporarily  discontinued and participants monitored for related symptoms 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
40 and with unscheduled MRIs at the investigator’s discretion. In the case of symptomatic ARIA -H, 
the investigator or designee should m onitor for changes in symptoms and may consider 
withholding study intervention. Upon  stabilization of ARIA -H and resolution of associated 
symptoms, reinitiating study intervention can be considered.  If stabilization  of imaging findings 
and resolution of as sociated symptoms  is not observed, participants should be permanently 
discontinued from study intervention, but continue other study activities.  
In the event of symptomatic ARIA -H, the investigator is to complete the ARIA Related Events 
CRF regarding the symptoms related to the ARIA -H, and ARIA -H should be reported as an AE 
in the AE CRF. Information regarding symptoms attributed to the ARIA -H event should be 
entered in the ARIA Related Events CRF and should not be reported as AEs.  
7.1.4.  Tempor ary Discontinuation  
Temporary discontinuation from study intervention  treatment is allowed secondary to 
hospi[INVESTIGATOR_059], personal or exceptional circumstances, or to evaluate the study intervention 
impact on an uncertain AE.  
Study inte rvention may be restarted at the investigator’s discretion.  
If temporary discontinuation is due to an AE, it should be reported to the sponsor -designated 
medical  monitor. Temporary treatment discontinuation and re -starting should be documented.  
Restarting  treatment after a discontinuation period that is greater than 12 weeks should be 
discussed between the investigator and sponsor -designated medical monitor . 
7.2. Participant Discontinuation/Withdrawal from the Study  
A participant may withdraw from the study  
● at any time at the participant’s own request  
● at the request of the participant’s designee (for example, parents or legal 
guardian)  
● at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
● if enro llment in any other clinical study involving an investigational product or 
enrollment in any other type of medical research judged not to be scientifically or 
medically compatible with this study , or 
● if the participant, for any reason, requires treatment  with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new agent.  
Discontinuation is expected to be uncommon.  
At the time of disco ntinuing from the study, if possible, an early discontinuation  visit should be 
conducted, as shown in the SoA. See SoA for data to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed. Th e 
participant will be permanently discontinued from both the study intervention and the study at 
that time.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
41 If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such  a withdrawal of consent. If a participant 
withdraws from the study, he/she may request destruction of any samples taken and not tested, 
and the investigator must document this in the site study records.  
7.3. Lost to Follow up  
A participant will be  considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. Site personnel or designee are 
expected to make diligent attempts to contact [CONTACT_10971] a s cheduled visit 
or were otherwise unable to be followed up by [CONTACT_779].  
Site personnel, or an independent third party, will attempt to collect the vital status of the 
participant within legal and ethical boundaries for all participants randomized, including  those 
who did not get investigational product. Public sources may be searched for vital status 
information. If vital status is determined to be deceased, this will be documented and the 
participant will not be considered lost to follow -up. Sponsor personn el will not be involved in 
any attempts to collect vital status information.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
42 8. Study Assessments and Procedures  
● Study procedures and their timing are summarized in the SoA.  
● Immediate safety concerns should be discussed with the sponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention.  
● Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct.  
● All screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participants screened and to confirm 
eligibility or record  reasons for screening failure, as applicable.  
8.1. Efficacy Assessments  
8.1.1.  Biomarker Efficacy Measures  
Florbetapir F18 PET scan  
Change in amyloid burden (as assessed with florbetapir F18 PET  by [CONTACT_541439] ) will be compared in donane mab and aducanumab -treated participants.  
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Vital Signs  
For each participant, vital signs measurements should be conducted according to the S oA 
(Section  1.3) and following the study -specific recommendations included in Manual of 
Operations for the study . 
8.2.2.  Electrocardiograms  
For each participant, single 12 -lead digital ECGs will be collected during  the screening period, 
according to the SoA ( Section  1.3) using an ECG machine that automatically calculates the heart 
rate and measures PR, QRS, QT , and QTc intervals. Refer to Section 7.1.[ADDRESS_705988] be supi[INVESTIGATOR_51938] 5 to 10 minutes before ECG collection and remain supi[INVESTIGATOR_105305].  
Electrocardiograms may be obtained at  additional times, when deemed clinically necessary.  
Electrocardiograms will be interpreted by a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collection as possible, and ideally while the 
participan t is still present, to determine whether the participant  meets entry criteria at the relevant 
visit(s) and for immediate participant management, should any clinically relevant findings be 
identified.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
43 After enrollment, if a clinically significant increase i n the QT/QTc interval from baseline or 
other clinically significant quantitative or qualitative change from baseline is identified, the 
participant will be assessed by [CONTACT_324010] (e.g., palpi[INVESTIGATOR_814], near syncope, 
syncope) and to determi ne whether the participant can continue in the study. The investigator or 
qualified designee is responsible for determining if any change in participant management is 
needed.  
The investigator (or qualified designee) must document his/her review of the ECG  printed at the 
time of collection and any alert reports . 
8.2.3.  Clinical Safety Laboratory Tests  
● See Appendix [ADDRESS_705989] of clinical laboratory tests to be performed and the 
SoA for the timing and frequency.  
● The investigator must review the laboratory results, document this review, and 
report any clinically relevant changes occurring during the study as an AE. The 
laboratory results must be retained with source documents unless a Source 
Document Agreement or c omparable document cites an electronic location that 
accommodates the expected retention duration. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, 
unless judged by [CONTACT_2418] m ore severe than expected for the 
participant's condition.  
● All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within the follow -up period  after the last dose 
of study intervention  after the l ast dose of study intervention should be repeated 
until the values return to normal or baseline or are no longer considered clinically 
significant by [CONTACT_10982].  
○ If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified and the 
sponsor notified.  
○ All protocol -required laboratory assessments, as defined in Appendix 2, must 
be conducted in accordance with the SoA, standard collection requirements , 
and laboratory manual . 
● If laboratory values from non -protocol specified laboratory assessments 
performed at an investigator -designated local laboratory require a change in 
participant management or are considered clinically significant by [CONTACT_32595] 
(e.g., SAE or AE or dose modification), then report the information as an AE.  
8.2.4.  Suicidal Ideation and Behavior Risk Monitoring  
Participants being treated with study intervention  should be monitored appropriately and 
observed closely for SIB or any other unusual changes in behavior, especially at the beginning 
and end of the course of intervention, or at the time of dose changes, either increases or 
decreases. Participants who expe rience signs of SIB should undergo a risk assessment. All 
factors contributing to SIB should be evaluated and consideration should be given to 
discontinuation of the study intervention . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
44 Baseline assessment of SIB and intervention -emergent SIB will be monit ored during Study 
AAC N using the C -SSRS.  
C-SSRS  
C-SSRS is a scale that captures the occurrence, severity, and frequency of SIB during the 
assessment period via a questionnaire. The scale was developed by [CONTACT_541449] C -CASA categorization of suicidal events.  
8.2.5.  Magnetic Resonance Imaging  
MRI of the brain will be performed according to the SoA (Section 1.3) and as clinically 
indicated.  Unscheduled MRIs may be performed at the discretion of investigator.  
This technology will be used to check for evidence of ARIA -H or ARIA -E, and other clinically  
relevant inclusion/exclusion and safety findings.  
The MRI scans will be reviewed by [CONTACT_541450]. Any clinically significant findings noted at baseline that result in a 
diagnosis should be rec orded as a preexisting condition or AE. MRI scans are read locally and 
will be sent for analysis to a centralized MRI vendor  (blinded to treatment allocation)  designated 
by [CONTACT_11007]. Final MRI eligibility at screening will be determined by [CONTACT_541451] “does” or “does 
not” meet MRI eligibility criteria.  
Specific analyses of the scans, including assessments of ARIA -H and ARIA -E, will be 
interpreted by [CONTACT_541452] M RI vendor for data analysis and report -writing purposes.  
Results of centrally read MRIs regarding p articipant  care/safety will be reported back to the 
investigator.  
8.2.6.  Hepatic Safety Monitoring  
Close hepatic monitoring  
Laboratory tests (Appendix 6, Section 10.6), including ALT, AST, ALP, TBL, D. Bil, GGT, and 
CK, should be repeated within 48 to 72 hours to confirm the abnormality and to determine if it is 
increasing or decreasing, if one or more of t hese conditions occur:  
If a participant with baseline 
results of ...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participants  with 
Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  

CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
45 ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for participants  
with Gilbert’s syndrome)  
 
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_61520] -designated medical monitor. At a minimum, this eva luation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-counter), herbal and dietary supplements, history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical co ndition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and lab results stabilize. Monitoring of ALT, AST, ALP, and 
TBL should continue until levels  normalize or return to approximate baseline levels.  
Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
one or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptomsa, or  
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participants  with Gilbert’s 
syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs/symptomsa, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for participants  with Gilbert’s 
syndrome)  
 a Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
46 At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as  well as tests for PT -INR; tests for viral hepatitis A, B, C, or E; tests 
for autoimmune hepatitis; and an abdominal imaging study (for example, ultrasound or CT scan).  
Based on the participant’s  history and initial results, further testing should be consi dered in 
consultation with the Lilly -designated medical monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen, Wilson’s disease, blood alcohol level s, urinary ethyl glucuronide, and 
blood phosphatidylethanol. Based on the circumstances and the investigator’s assessment of the 
participant’s clinical condition, the investigator should consider referring the participant for a 
hepatologist or gastroentero logist consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liv er tests during the study  
Additional hepatic safety data collection in hepatic safety CRF should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT to ≥[ADDRESS_705990] on 2 or more consecutive blood tests (if baseline 
ALT <1.5x ULN)  
 In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline on 2 
or more consecutive tests  
2. Elevated TBL to ≥ [ADDRESS_705991] (if baseline TBL <1.5x ULN) (except for cases of kn own 
Gilbert’s syndrome)  
 In participants with baseline TBL ≥1.5x ULN, the threshold should be TBL ≥2x 
baseline  
3. Elevation of serum ALP to ≥[ADDRESS_705992] on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)  
 In participants with baseline ALP ≥1.5x ULN, th e threshold is ALP ≥2x baseline on 2 
or more consecutive blood tests  
4. Hepatic event considered to be a SAE  
5. Discontinuation of study drug due to a hepatic event  
Note: the interval between the two consecutive blood tests should be at least [ADDRESS_705993] Complaints  
The definitions of the following events can be found in Appendix 3:  
 AEs 
 SAEs  
 PCs 
These events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the p articipant's legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
47 are serious, cons idered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study intervention or study (see Section 6.8.3 ). 
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs and AEs of special interest (as defined in Section 8.3.4) will 
be followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow -up (as defined in Section 7.3). For PCs, the investigator is responsible for ensuring 
that follow -up includes any supplemental investigations as indicated to elucidate the nature 
and/or causality. Further information on follow -up procedure s is provided in Appendix 10.3. 
8.3.1.  Timing and Mechanism for Collecting Events  
This table describes the timing, deadlines, and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
Adverse Event  
AE Signing of 
the ICF  Participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
Serious Adverse Event  
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
with study 
procedures  or 
occurring after 
receiving PET 
tracer  Signing of 
the ICF  Start of 
intervention  Within 24  hours of 
awareness  SAE CRF  SAE paper 
form  
SAE and SAE 
updates – after 
start of study 
intervention  Start of 
intervention  Participation 
in study has 
ended  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
48 Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for 
Reporting  Back -Up 
Method of 
Reporting  
SAEa – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants and 
female partners 
of male 
participants  After the 
start of study 
intervention  [ADDRESS_705994] dose  Within 24  hours (see 
Section 8.3.2 ) Pregnancy paper 
form  N/A 
Product Complaints  
PC associated 
with an SAE or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24  hours of 
awareness  PC form  N/A 
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed PC form 
with all changes 
signed and dated by 
[CONTACT_093]  N/A 
PC (if 
investigator 
becomes aware)  Participation 
in study has 
ended  N/A Promptly  PC form   
Abbreviations: AE = adverse event; CRF = case reporting form;  ICF = informed consent form; N/A = not 
applicable; PC = product complaint; PET = positron emission tomography ; SAE = serious adverse event.  
a SAEs after study participation  should not be reported unless the investigator deems them to be possibly related to 
study treatment or study participation.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705995] pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant 
is in this study. This applies only to male participants who receive study 
intervention . 
b. After learning of a pregnancy in the  female partner of a study participant, the 
investigator will  
a. obtain a consent to release information from the pregnant female 
partner directly, and  
b. within [ADDRESS_705996] pregnancy 
information on the appropriate form and submit it to the sponsor.  
The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to 
the sponsor. Generally, the follow -up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of gestational age,  fetal status (presence or absence of 
anomalies) or indication for the procedure.  
Female participants who become pregnant  
a. The investigator  will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial 
information will be recorded on the appropriate form and submitted to the 
sponsor within 24 hours of learning of a participant 's pregnancy.  
b. The participant will be followed to determine the outcome of the pregnancy. 
The investigator will collect follow -up information on the participant and the 
neonate and the information will be forwarded to the sponsor. Generally, 
follow -up wil l not be required for longer than 6 to 8 weeks beyond the 
estimated delivery date. Any termination of pregnancy will be reported, 
regardless of gestational age,  fetal status (presence or absence of anomalies) 
or indication for the procedure.  
c. While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will 
be reported as an AE or SAE.  
d. A spontaneous abortion (occurring at <20 weeks gestational age) or still b irth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE 
and will be reported as such.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705997] discontinuation  process and continue directly to the 
follow -up phase. The follow -up on the pregnancy outcome should continue 
independent of intervention or study discontinuation.  
8.3.3.  Hypersensitivity Including Infusion -Related Reactions  
[IP_ADDRESS].  Management of Infusion -Related Reacti ons  
If a systemic hypersensitivity reaction occurs, additional data describing each sign or symptom 
should be provided to the sponsor in the Hypersensitivity, Anaphylactic, and Infusion -Related 
Reactions CRF. Participants who experie nce a systemic hypersensitivity, should have vital signs 
collected.  
Locations where study participants are receiving study intervention should have appropriately 
trained medical staff and appropriate resuscitation equipment and rescue measures. It is 
recom mended that participants who experience a systemic hypersensitivity reaction be treated 
per the local standard of care.  
If a participant experiences a systemic hypersensitivity reaction or infusion -related reaction 
either involving 2 or more organ systems (for example, mucocutaneous, respi[INVESTIGATOR_696], 
cardiovascular, or gastrointestinal systems), or that is severe, additional blood and urine samples 
should be collected as close to the event as possible, as described in Section 10.2.1 . Tryptase and 
when applicable urine N-methylhistamine should be repeated in approximately 4  weeks (and 
prior to the next infusion, if applicable) to obtain post -event baseline. Laboratory results are 
provided to the sponsor via the central laboratory and are not needed for clinical management  of 
the participant.  
[IP_ADDRESS].  Dosing Rechallenge and Premedication for Infusions  
Donanemab  
Premedication for dosing is not planned. Dosing rechallenge is contraindicated in participants 
that have experienced a suspected or possible anaphylact ic reaction (for example, reaction 
involving 2 or more organ systems [for example, mucocutaneous, respi[INVESTIGATOR_696], cardiovascular, or 
gastrointestinal systems] occurring in close proximity to dosing), in a prior dose (Sampson et al. 
2006). For infusion -related  reactions which are not suspi[INVESTIGATOR_541424], at the 
investigator’s discretion, the participant may continue to receive study intervention. The 
participant may be premedicated for subsequent doses at investigator’s discretion and according 
to local practice guidelines. Any premedication given will be documented as a concomitant 
therapy (Section  6.8). 
Aducanumab  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_705998] for this study include, but are not limited to, the following:  
 ARIA -E 
 ARIA -H 
 Hypersensitivity, immediate and non -immediate, including infusion -related reactions 
and anaphylaxis  
The topi[INVESTIGATOR_541425], as well as other topi[INVESTIGATOR_541426], will be subject to enhanced surveillance activities. Additionally, the topi[INVESTIGATOR_541427].  
8.4. Pharmacokinetics  
a. Serum  samples will be collected for measurement of serum  concentrations of study 
intervention as specified in the SoA . 
b. The timing of sampling may be altered during the course of the study based on newly 
available data (e.g., to obtain data closer to the time of peak plasma concentrations) to 
ensure appropriate monitoring.  
c. Instructions for the collection and handling of biological samples will be provided by 
[CONTACT_456]. The act ual date and time (24 -hour clock time) of each sample will be 
recorded.  
d. Bioanalytical samples collected to measure study intervention will be retained for a 
maximum of [ADDRESS_705999] participant  visit for the study. During this time, 
samples remaini ng after the bioanalyses may be used for exploratory analyses such as 
metabolism, protein binding, or bioanalytical method development/validation work.  
8.5. Pharmacodynamics  
Pharmacodynamic parameters are not evaluated in this study.  
8.6. Genetics  
8.6.1.  Apolipoprotein E G enotypi[INVESTIGATOR_541428] a mandatory part of this study. Blood sampling for ApoE genotypi[INVESTIGATOR_541429]. Neither participants nor investigators will receive the genotype 
results unless there is a country -specific law or regulation that requires notification of the results.  
8.6.2.  Whole Blood Samples for Pharmacogenetic Research  
A blood sample for DNA isolation will be collected from participants.  
See Appendix 5, Section  10.5 for information regarding genetic research and Appendix 1, 
Section  10.1.12  for details about sample retention and custody . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
52 8.7. Biomarkers  
Biomarker research is performed to address questions of relevance to drug disposition, target 
engagement, PD, mechanism of action, variability of p articipant  response (including safety), and 
clinical outcome. Sample collection is incorporated into clinical studies to enable examination of 
these questions through measurement of biomolecules including proteins, lipi[INVESTIGATOR_805], and other 
cellular elements.  
Serum  and plasma, samples for biomarker research will be collected at the times specified in the 
SoA ( Section  1.3) where local regulations allow.  
Samples will be  used for research on the drug target, disease process, variable response to study 
intervention , pathways associated with AD, mechanism of action of study intervention , and/or 
research method or in validating diagnostic tools or assay(s) related to AD or o ther neurological 
conditions.  
All samples will be coded with the p articipant  number. These samples and any data generated 
can be linked back to the p articipant  only by [CONTACT_10991].  
Samples will be retained  per Section 10.1.12 . 
8.8. Immunogenicity Assessments  
At the visits and times specified in the SoA (Section  1.3), venous blood samples will be collected 
to determine antibody production against donanemab.  Antibodies may be further characterized 
and/or evaluated for their ability to neutralize the activity of donanemab. To interpret the results 
of immunogenicity, a venous blood sample will be collected at the same time points to determine 
the serum concentra tions of donanemab. All samples for immunogenicity should be taken 
predose when applicable and possible.  
Immunogenicity will be assessed by a validated assay designed to detect ADAs in the presence  
of donanemab at a laboratory approved by [CONTACT_456].  
Treatment -emergent ADAs are defined in Section [IP_ADDRESS] . If the immunogenicity sample at the  
last scheduled assessment or discontinuation visit is TE ADA positive, additional samples may  
be taken for up to approximately [ADDRESS_706000] dose.  
Samples will be retained per Section 10.1.12 . 
8.9. Health Economics  
Health economics or medical resource utilization and health economics parameters are not 
evaluated in this study . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_706001] for the primary analyses (for both ITT and the intermediate tau 
subpopulation ) are: 
 pdona ,6m: the probability that a participant  will achieve complete brain amyloid clearance 
at 6 months under the donanemab treatment regimen.  
 padu, 6m: the probability that a participant  will achieve complete brain amyloid clearance at 
6 months under the aducanuma b treatment regimen . 
Odds ratio:  OR 6m = [(p dona,6m )/(1- pdona,6m )]/[(p adu,6m )/(1- padu,6m )] 
                       
The null and alternative (1-sided) hypotheses to be tested are:  
 H0: OR 6m = 1 
 HA: OR 6m > 1 
The odds ratio  for the overall population and for the intermediate tau subpopulation will be 
estimated using  logistic regression model s as described in Section 9.3. The analyses of the two 
primary end points and the key secondary endpoints will be controlled to be under a 2-sided 
Type 1 error rate of 5%, or equivalently, a 1-sided rate of 2.5%. The details regarding the testing 
scheme for these analyses will be desc ribed in the SAP.  
9.2. Analyses Sets  
For the purposes of analysis, the following analysis sets are defined:  
Participant Analysis Set  Description  
Full analysis set  / ITT 
analysis set  All randomized participants  with baseline and  at least one  post-
baseline amyloid PET scan . Participants will be included in the 
analyses according to the planned intervention.  
Intermediate tau set  All randomized participants with baseline and at least one post -
baseline amyloid PET scan and a baseline flortaucipi r F18  PET 
scan meeting the intermediate tau criteria .  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
54 Participant Analysis Set  Description  
Safety analysis set  All participants who are exposed to study intervention. 
Participants will be analyzed according to the intervention they 
actually received.  
The full analysis and intermediate tau sets are used to analyze endpoints related to the amyloid 
plaque objectives and the safety analysis set is used to analyze the endpoints and assessments 
related to safety.  
9.3. Statistical Analyses  
9.3.1.  General Considerations  
Statistical analysi s of this study will be the responsibility of  the Sponsor  or its designee.  
Unless otherwise noted, tests of treatment effects will be conducted at a 2 -sided alpha level of 
0.05 (or equivalently, a 1 -sided 0.025 alpha level); 2 -sided CIs will be displayed w ith a 95% 
confidence level. All tests of interactions between treatment and other factors will be conducted 
at an alpha level of 0.05.  
A suitable approach such as  Bretz’s graphical approach may be utilized to provide strong control 
of the study wise Type I  error rate for the primary and key secondary hypotheses at an alpha 
level of 0.05 (Bretz et al. 2009; Bretz et al. 2011). Details on the graphical approach and testing 
strategy will be specified in the SAP  prior to the first participant  visit. 
All amyloid  plaque  analyses will follow the ITT principle unless otherwise specified. An ITT 
analysis is an analysis of data by [CONTACT_541453] s are assigned by [CONTACT_541454], even if the participant  does not take the assigned treatment, does not receive the 
correct treatment, or otherwise does not follow the protocol.  
When change from baseline is assessed, participant s will be included in the analysis only if both 
a baseline and a postbaseline measure are available. Unless otherwise defined, a baseline 
measure is the last nonmissing observation collected prior to the first administration of study 
medications. Endpoint is the last nonmissing postbaseline measurement.  
To allow for sequential testing, database locks  and the testing of corresponding  primary and key 
secondary objectives  are expected to occur after all randomized participant s have had a chance to 
complete the scheduled [ADDRESS_706002] participant visit  and it will include a more technical and 
detailed description of the statistical analyses described in this section. This section is a summary 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_706003] important endpoints includ ing primary and key 
secondary endpoints.   
[IP_ADDRESS].  Handling of Missing Data for Efficacy Endpoints  
For most efficacy endpoints,  participant s will be included in the analysis only if baseline and at 
least one post -baseline measurement are available. For most endpoin ts analyzed after the [ADDRESS_706004] or other imputation -based 
techniques for handling  missing data may be considered and will be detailed in the SAP.  
9.3.2.  Treatment Group Comparability  
[IP_ADDRESS].  Participant Disposition  
All participants who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation will be 
given.  
When a participant discontinues from the study, the reason(s) will be collected and will be 
summarized by [CONTACT_541455]. The percentage of participants 
discontinu ing from each treatment group will be compared between groups using Fisher’s exact 
test. The comparisons will be done for the overall percentage of participants who discontinue and 
for select specific reasons for discontinuation.  
[IP_ADDRESS].  Participant Characteristic s 
The participant’s age, sex, race, height, body weight, body mass index (weight (kg)/[height 
(m)]2), ApoE ε4 genotype, MMSE , CDR -global score , and having [ADDRESS_706005] degree 
relatives with AD at baseline will be recorded.  
Baseline characteristics will be summarized by [CONTACT_541456].  
Summaries will include descriptive statistics for continuous and categorical measures. Fisher’s 
exact test or Pearson’s chi -square test will be used for treatment group comparisons of 
categorica l data. For continuous data, analysis of variance, with independent factors for 
treatment and investigator, will be used.  
[IP_ADDRESS].  Prior and Concomitant Therapy  
Prior medications are defined as those that stop before randomization (Visit 2). Concomitant 
medications  are defined as those being taken on or after randomization (Visit 2). A summary of 
concomitant medications will be presented as frequencies and percentages for each treatment 
group. Fisher’s exact test will be used to test for treatment differences betwee n groups.  
If the start or stop dates of therapi[INVESTIGATOR_511082], the therapy will be deemed concomitant.  
Prior and concomitant medications will be liste d. 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_706006] cognitive 
function and acetyl -cholinesterase -inhibitor /memantine medications.  
Medications will be coded using the World Health Organization drug dictionary.  
[IP_ADDRESS].  Treatment Comp liance  
Summary statistics for treatment compliance will be provided for the total number of complete 
infusions received, duration of complete infusion, and volume of complete infusion by [CONTACT_6490].  
Frequencies and percentages of reasons why infusion was stopped will also be presented.  
9.3.3.  Primary Analys es 
Proportion of Participants with Amyloid Plaque Clearance at [ADDRESS_706007] of treatment from this logistic 
regression model. Treatment effects will be presented using odds ratios and 95% confidence 
intervals. This analys is will be conducted on the full ITT population and the intermediate tau 
subpopulation.  
9.3.4.  Secondary Analys es 
The mean change from baseline in amyloid plaque levels  at months 6, 12, and 18, and the time to 
amyloid plaque clearance are the four key secondary endpoints. It is expected that these 
endpoints will be analyzed sequentially  as data for them are available. That is, for any efficacy 
analyses for  6-month /12-month/18-months  endpoints , data will be available at baseline  and for 
all timepoints up  to and including the time point in question.  
[IP_ADDRESS].  Mean Change from Baseline in Amyloid Plaque  
Consequently, mean change from baseline in amyloid plaque levels at Month [ADDRESS_706008], and APOE e4 genotype, and baseline amyloid levels as the covariates. For the analysis 
of mean change from baseline at 12 and 18 months, a sepa rate mixed model repeated measures 
(MMRM) analysis with data up to that specific time point will be used. This model will include 
the fixed effects of treatment, time, and treatment by [CONTACT_6491], and APOE e4 genotype, 
and baseline amyloid level as c ovariates. Correlation among repeated measures on the same 
subject will be accounted for by [CONTACT_541457]. If the unstructured covariance structure matrix results in a lack of convergence, the 
following structures will be used in sequence until convergence is reached: heterogeneous 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_706009] -Roger approximation will be used to estimate the denominator degrees of freedom . 
[IP_ADDRESS].  Time to Amyloid Plaque Clearance  
Time to amyloid plaque clearance between the two treatment groups will be analyzed and 
compared using a log -rank test fo r survival data. Time to amyloid plaque clearance is defined as 
the earliest time (6/12/18 months) at which the participant reaches plaque levels below a certain 
pre-defined threshold. Subjects who do not have their plaque cleared by [CONTACT_541458]. Kaplan -Meier estimates of percent of 
patients reaching amyloid plaque clearance and p -value from the l og-rank test will be used to 
determine the superiority of donanemab  vs aducanumab in lowering time to plaque clearance. 
Additionally, time to plaque clearance may also be analyzed using a Cox proportional -hazards 
model. More details on these analyses will be provided in the SAP as appropriate . 
[IP_ADDRESS].  Proportion of Participants  with Amyloid Plaque Clearance  
The [ADDRESS_706010] aque 
clearance status (Yes/No) measurements and will be analyzed using separate generalized linear 
mixed model (PROC GLIMMIX) as pseudo -likelihood -based mixed effects repeated measures 
analysis assuming binomial distribution with a logit link. These models will be analyzed using 
data for outcomes up to and including the time point in question. The GLIMMIX model will 
include fixed effects for treatment, month, treatment -by-month interaction, APOE e4 genotype, 
and baseline amyloid leve l as covariates. An unstructured variance -covariance matrix will be 
used to model the correlation among repeated measures on the same individual. If model 
convergence is not reached, as planned for the MMRM analyses, lesser restrictive variance -
covariance structures will be employed until model convergence is attained.  
[IP_ADDRESS].  Other Outcomes  
Analyses of other secondary outcomes such as mean percent change in amyloid levels from 
baseline at 6, 12, and [ADDRESS_706011] squares mean differences or odds ratios along 
with 95% confidence intervals using appropriate contrasts for the treatment main effect or the 
treatment by [CONTACT_541459] m statistical models described above. Further details on 
analyses for other secondary or exploratory outcomes including defining margins for non -
inferiority analyses will be described in the SAP.  
9.3.5.  Other Safety Analyses  
All safety analyses will be made on th e safety population. Refer to the SAP for additional details.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
58 9.3.6.  Other Analyses  
[IP_ADDRESS].  Pharmacokinetics Analyses  
Data from this study may be combined with data from other studies to better characterize the PK 
of donanemab, as well as to explore the relationship betw een exposure and efficacy and/or safety 
outcomes. In this case, a separate PK analysis plan will be developed, and the results of these 
analyses will be described in a separate PK report.  
[IP_ADDRESS].  Evaluation of Immunogenicity  
The frequency and percentage of partici pants  with preexisting ADA and with  TE-ADA to  
donanemab  may be tabulated.  
Treatment -emergent ADAs are defined as  those with a titer  2-fold (1 dilution) greater than the 
minimum required dilution if no ADAs were detected at baseline (treatment -induced ADA) or 
those with a 4 -fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at 
baseline (treatment -boosted ADA).  
The frequency of  neutralizing antibodies  may also be tabulated in  TE ADA+  participants . 
The relationship between the presence of antibodies and the PK parameters and PD response 
including safety and efficacy to  donanemab  may be assessed.  
[IP_ADDRESS].  Analysis of C -SSRS Data  
Suicide -related thoughts and behaviors occurring during treatment will be summarized based on 
responses to the C-SSRS consistent with the C -SSRS Scoring and Data Analysis Guide (C UIMC 
2016).  
9.4. Interim Analysis  
An interim analysis may occur for an early efficacy assessment of the primary objective . The 
timing of the interim analysis may occur when  a sufficient number  of participants ( for example, 
approximately 75-125) have had a chance to receive their [ADDRESS_706012]  an 
interim analysis in greater detail  as well as the testing scheme and alpha spending function to 
control the Type -I error  should the interim be performed . If the interim analysis is conducted, the 
analysis will be executed through an external DMC.  
9.5. Sample Size Determination  
Approximately 200 participants will be enrolled and randomized in a 1:1 ratio to the 2 treatment 
regimens ( donanemab and aducanumab ). It is expected that approximately 1 80 participant s will 
complete 6-month florbetap ir F18 PET scan s (approximately 90 per treatment regimen).  It is 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
59 further anticipated that approximately 50% of p articipants  randomized will belong to the 
intermediate tau subpopulation . 
This sample size will provide at least 98% power to demonstrate that donanemab is superior to 
aducanumab  in achieving complete amyloid brain plaque clearance individually at [ADDRESS_706013]  model assuming a logit link . 
The assumptions for this power calculation are that 35.7%, 50.1%, and 54.6% of donanemab  
treated participant s reach complete brain amyloid clearance at 6 months, 12 months, and 18 
months, respectively. The corresponding complete brain amyloid clearance percentages for 
aducanumab  treated participant s are assumed to be 3.0%, 22.8%, and 27.8% , respectively . The 
simulation for the power calculation and sample size determination was carried out in SAS 
Enterprise Guide Version 7.15  and all sample size estimates were obtained assuming a 2-sided 
significance level of 0.05 . 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
60 10. Supporting Documentation an d Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
● This study will be conducted in accordance with the protocol and with the 
following:  
○ Consensus ethical p rinciples derived from international guidelines including 
the Declaration of Helsinki and CIOMS International Ethical Guidelines  
○ Applicable ICH GCP Guidelines  
○ Applicable laws and regulations  
● The protocol, protocol amendments, ICF, Investigator Brochu re, and other 
relevant documents (for example, advertisements) must be submitted to an 
IRB/IEC by [CONTACT_22843]/IEC before 
the study is initiated.  
● Any amendments to the protocol will require IRB/IEC approval before  
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants.  
● The investigator will be responsible for the following:  
○ Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance  with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC  
○ Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures  
○ Providing oversight of study conduct for participants under their responsib ility 
and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations  
● Investigator sites are compensated for participation in the study as  detailed in the 
clinical trial agreement.  
10.1.2.  Financial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certifi cation or disclosure statements to the appropriate regulatory authorities. Investigators are 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
61 responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process  
● The investigator or the investigator’s representative will explain the nature of the 
study, including the risks and benefits, to the participant or the participant’s 
legally authorized representative  and answer all questions regarding the st udy. 
● Participants must be informed that their participation is voluntary. Participants or 
their legally authorized representatives will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH g uidelines, privacy and data protection requirements, where applicable, and 
the IRB/IEC or study center.  
● The medical record must include a statement that written informed consent was 
obtained before the participant was entered in the study and the date th e written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
● Participants must be reconsented to the most current version of the ICF(s) during 
their participation in the study.  
● A copy of the ICF(s) must b e provided to the participant or the participant’s 
legally authorized representative  and is kept on file.  
10.1.4.  Data Protection  
● Participants will be assigned a unique identifier by [CONTACT_456]. Any participant 
records, datasets or tissue samples t hat are transferred to the sponsor will contain 
the identifier only; participant names or any information which would make the 
participant identifiable will not be transferred.  
● The participant must be informed that the participant’s personal study -related data 
will be used by [CONTACT_10999]. The 
level of disclosure must also be explained to the participant who will be required 
to give con sent for their data to be used as described in the informed consent.  
● The participant must be informed that their medical records may be examined by 
[CONTACT_103083], by [CONTACT_216203] e IRB/IEC members, and by [CONTACT_9326].  
● The sponsor has processes in place to ensure data protection, information security 
and data integrity. These processes include appropriate contingency plan(s) for 
appropriate and timely re sponse in the event of a data security breach.  
10.1.5.  Committees Structure  
A DMC consisting of members external to Lilly will be established. The purpose of the 
establishment of the DMC is  for the potential to conduct  an early efficacy analysis for Study 
AAC N. If the interim analysis is not deemed necessary to be conducted  by [CONTACT_456],  the DMC 
will not be convened to review study  data. The DMC will consist of a  minimum of 3 members, 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_706014], see the instructions provided at www.vivli.org.  
10.1.7.  Data Quality Assurance  
● All participant data relating to the study will be recorded on p rinted or electronic 
CRFs unless transmitted to the sponsor or designee electronically (for example, 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
● The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source data 
documents.  
● QTLs will be pre -defined to identify systematic issues that can impact participant 
safety and/or reliability of study results. These pre -defined parameters will be 
monitored during the study and impor tant excursions from the QTLs and remedial 
actions taken will be summarized in the clinical study report . 
● Monitoring details describing strategy (for example, risk -based initiatives in 
operations and quality such as risk management and mitigation strateg ies and 
analytical risk -based monitoring), methods, responsibilities and requirements, 
including handling of noncompliance issues and monitoring techniques are 
provided in the Monitoring Plan.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
63 ● The sponsor or designee is responsible for the data managemen t of this study 
including quality checking of the data.  
● The sponsor assumes accountability for actions delegated to other individuals 
(e.g., contract research organizations).  
● Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently appr oved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
● Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_541460] a longer retention period. 
No records may be destroyed during the retention period without the written 
approval of the sponsor. No records may be transferred to another location or 
party wi thout written notification to the sponsor.  
● In addition, Sponsor or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be audited by [CONTACT_541461] s, and/or regulatory agencies at 
any time. Investigators will be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
An EDC system will be used in this study for the collection of CRF data. The investigator 
maintains a separate source for the data entered by [CONTACT_11002] -provided EDC system. The investigator is responsible  for the identification of any data 
to be considered source and for the confirmation that data reported are accurate and complete by 
[CONTACT_11003] . 
Additionally, COA data (participant -focused outcome instrument) and other data will be 
collected by [CONTACT_2299]/caregiver/authorized study personnel , via a paper source document 
and will be transcribed by [CONTACT_541462] . 
Data collected via the sponsor -provided data capture system (s) will be  stored (at third parties) . 
The investigator will have continuous access to the data during the study and until 
decommissioning of the data capture system . Prior to decommissioning, the investigator will 
receive or access an archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports/electronic transfers  will be provided to the 
investigator for review and retention. Data will subsequently be transferred f rom the central 
vendor to the sponsor data warehouse.  
Data from complaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management system.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
64 10.1.8.  Source Documents  
● Source documents provide evidence for the existence of  the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
● Data reported on or entered in the CRF and are transcribed from source 
documents must be consistent with the source documents or  the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records must be 
available.  
● Definition of what constitutes source data can be found in S ection 10.1.[ADDRESS_706015] been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
For study termination:  
 Discontinuation of further study intervention development  
For site termination:  
 Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor 's procedures, or GCP guidelines  
 Inadequate recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_093]  
 Total number of participants included earlier than expected.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The  investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
65 10.1.10.  Publication Policy  
In accordance with the sponsor’s publication policy, the results of this study will be submitted 
for pub lication by a peer -reviewed journal.  
10.1.11.  Investigator Information  
Researchers with appropriate education, training, and experience, as determined by [CONTACT_456], 
will participate as investigators in this clinical trial.  
10.1.12.  Sample Retention  
Sample retention enable s use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development of  the 
study intervention . 
Sample Type  Custodian  Retention Period 
After Last Participant  
Visita 
Biomarkers  Sponsor or Designee  15 years  
PK Sponsor or Designee  1 year  
Genetics  Sponsor or Designee  15 years  
Immunogenicity  (ADA)  Sponsor or Designee  15 years  
Abbreviations:  ADA = anti -drug antibody; PK = pharmacokinetic. 
a Max potential retention unless local requirements differ . 
  
  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
66 10.2. Appendix 2: Clinical Laboratory Tests  
 The tests detailed in the table below will be performed by [CONTACT_2237] 
(unless specified otherwise below).  
 Local laboratory results are only required in the event that the central laboratory 
results are not available in time for either study intervention administration and/or 
response evaluation. If a local sample is required, it is important that the sample 
for central analysis is obtained at the same time. A dditionally, if the local 
laboratory results are used to make either a study intervention decision or 
response evaluation, the results must be recorded.  
 In circumstances where the sponsor approves local laboratory testing in lieu of 
central laborat ory testing (in the table below), the local laboratory must be 
qualified in accordance with applicable local regulations.  
 Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
 Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
 Investi gators must document their review of the laboratory safety results.  
Clinical Laboratory Tests  Comments  
Hematology  Assayed by [CONTACT_11007] -designated laboratory  
Hemoglobin    
Hematocrit    
Erythrocyte count (RBCs - Red Blood Cells)    
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration    
Leukocytes (WBCs - White Blood Cells)    
Differential    
   Neutrophils, segmented   
   Lymphocytes    
   Monocytes    
   Eosinophils    
   Basophils    
Platelets    
Cell morphology (RBCs and WBCs)    
    
Clinical Chemistry  Assayed by [CONTACT_11007] -designated laboratory  
Sodium    
Potassium    
Chloride    
Bicarbonate    
Total bilirubin    
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
[ADDRESS_706016] bilirubin    
Alkaline phosphatase (ALP)    
Alanine aminotransferase (ALT)    
Aspartate aminotransferase (AST)    
Gamma -glutamyl transferase (GGT)    
Blood urea nitrogen (BUN)    
Creatinine    
Creatine kinase (CK)    
Uric acid    
Albumin    
Calcium    
Glucose    
Cholesterol    
    
PK Samples – donanemab  and aducanumab  
concentration  Assayed by [CONTACT_11007] -designated laboratory.   
Results will not be provided to the investigative sites.  
  
Biomarkers  
Additional Testing  Assayed by [CONTACT_11007] -designated laboratory.   
Apolipoprotein E (ApoE)  Results will not be provided to the investigators.  
  
Genetics Sample  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigators.  
    
Exploratory Biomarker Storage Samples  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigators.  
   Serum    
   Plasma (EDTA)    
  
Immunogenicity (ADA)  Samples  Assayed by [CONTACT_11007] -designated laboratory.  
Results will not be provided to the investigators.  
   Anti-donanemab antibodies    
   Anti-donanemab antibodies neutralization    
 
 
 
10.2.1.  Clinical Laboratory Tests  for Hypersensitivity Events  
 Laboratory assessments should be performed if the participant experiences 
generalized urticaria or if anaphylaxis or angioedema is suspected.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
68  Collect sample after the participant has been stabilized, and within 1 to 2  hours of  
the event; however, samples may be obtained as late as [ADDRESS_706017] the time at 
which the sample was collected.  
 Sample should be repeated in approximately 4 weeks (and prior  to the next 
infusion, if applicable)  to obtain post -event baseline . 
The table below  summarizes the laboratory parameters that will be evaluated. These laboratory 
tests are bundled in the hypersensitivity laboratory testing kit.  
Hypersensitivity Tests  Note s 
Selected test may be obtained in the event of anaphylaxis or systemic 
allergic/hypersensitivity reactions.  
   donanemab   ADAs 
(immunogenicity/ADA)  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
   donanemab   concentrations 
(PK)  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
   Tryptase  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
Note :  
Optimally collected between [ADDRESS_706018] if >[ADDRESS_706019] passed since the hypersensitivity event.  
If a tryptase sample is obtained more than 2  hours after the event (that is, 
within 2 to 12  hours), or is not obtained because mo re than [ADDRESS_706020] void urine sample following the event. Tryptase and when 
applicable urine N-methylhistamine should be repeated in approximately 4 
weeks (and prior to the next infusion, if applicable) to obtain post -event 
baseline.  
   N-methylhistamine  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
   Drug -specific IgE  Will be performed if a validated assay is available.  
Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
   Basophil activation test  Will be performed if a validated assay is available.  
Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
Note:  The basophil activation test is an in vitro cell -based assay that only 
requi res a serum sample. It is a surrogate assay for drug -specific IgE but is not 
specific for IgE.  
CONFIDENTIAL  Protocol number I5T -MC-AACN (b) 
69 Abbreviations: ADA = antidrug antibody; IgE = immunoglobulin E; IL = interleukin; PK = pharmacokinetic.   Complement (C3, C3a, and 
C5a)  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
   Cytokine panel (IL‐6, IL‐
1β, and  IL‐10)  Assayed by [CONTACT_11007] -designated laboratory. Results will not be provided to the 
investigators.  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
70 10.3. Appendix 3: Adverse Events and Serious Adverse Events: Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting  
10.3.1.  Definition of AE  
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not n ecessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a medi cinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
 
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (for example, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (that is, not related 
to progression of underlying disease) . 
 Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have been present  before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will  not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
 Lack of efficacy or failure of expected pharmacological action per se will not be  
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfill the definition of an AE or SAE.  
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_541463]’s condition.  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
71  The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
 Medical or surgical procedure (for example, endos copy, appendectomy): the condition 
that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of pre -existing disease(s) o r condition(s) present or 
detected at the start of the study that do not worsen.  
10.3.2.  Definition of SAE  
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or 
more of the criteria listed:  
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires  inpatient hospi[INVESTIGATOR_1081]  
 In general, hospi[INVESTIGATOR_541430] (usually involving at least an overnight stay) for observation and/or 
treatmen t that would not have been appropriate in the physician’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication 
prolongs hospi[INVESTIGATOR_9236], the event is serious. When 
in doubt as to whether hospi[INVESTIGATOR_51956], the AE should be 
considered serious.  
 Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disab ility/incapacity  
 The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, naus ea, vomiting, diarrhea, influenza, 
and accidental trauma (for example, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
72 e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
f. Other situations:  
 Medical or scientific judgment should be exercised by [CONTACT_541464] -threatening or result in death or hospi[INVESTIGATOR_541431] o utcomes listed in the above definition. These events should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse.  
10.3.3.  Definition of Product Complaints  
Product Complaint  
 A product complaint is any written, electronic, or oral communication that alleges 
deficiencies related to  the identity, quality, durability, reliability, safety, effectiveness 
or performance of a study intervention . When the ability to use the study intervention 
safely is impacted, the following are also product complaints:  
o Deficiencies in labeling informatio n, and  
o Use errors for device or drug -device combination products due to ergonomic 
design elements of the product.  
 Product complaints related to study interventions used in clinical trials are collected in 
order to ensure the safety of participants, monitor  quality, and to facilitate process and 
product improvements.  
 Investigators will instruct participants to contact [CONTACT_11010] a product complaint or problem with the study intervention so that the situation can 
be assessed . 
 An event may meet the definition of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.  
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product Complaints  
AE, SAE , and Product Complaint Recording  
 When an AE/SAE /PC occurs, it is the responsibility of the investigator to review all 
documentation (for example, hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event.  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
73  The investigator  will then record all relevant AE/ SAE/ PC information in the 
participant’s medical records, in accordance with the investigator’s normal clinical 
practice. AE/SAE information is reported on the appropriate CRF page and PC 
information is reported on the PC Form. 
Note: An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a product complaint and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee in lieu of completion of the CRF page for AE/SAE and 
the PC Form for PCs. 
 There may be instances when copi[INVESTIGATOR_541432]. In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_51959].  
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:  
 Mild: A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event  does not generally interfere with usual 
activities of daily living.  
 Moderate: A type of adverse event that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living, 
causing discomf ort but poses no significant or permanent risk of harm to the research 
participant.  
 Severe: A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention. An AE th at is 
assessed as severe should not be confused with a SAE. Severe is a category utilized for 
rating the intensity of an event; and both AEs and SAEs can be assessed as severe.  
An event is defined as ‘serious’ when it meets at least one of the predefined o utcomes 
as described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relationship  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
74  A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 Alternative causes, such  as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
 The investigator will also consult the IB and/or Product Inf ormation, for marketed 
products, in their assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred  and the investigator has 
minimal information to include in the initial report to Sponsor or designee. However, it 
is very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE dat a to Sponsor or designee.  
 The investigator may change their opi[INVESTIGATOR_9242] -up 
information and send a SAE follow -up report with the updated causality assessment.  
 The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_226428]/or causality of the AE or SAE as fully as possible. 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
 If a participant dies during participat ion in the study or during a recognized follow -up 
period, the investigator will provide Sponsor or designee with a copy of any 
post-mortem findings including histopathology.  
10.3.5.  Reporting of SAEs  
SAE Reporting via an Electronic Data Collection Tool  
 The primary mechanism for reporting an SAE will be the electronic data collection 
tool. 
 If the electronic system is unavailable, then the site will use the SAE paper form (see 
next section) in order to report the event within 24 hours.  
 The site will enter the  SAE data into the electronic system as soon as it becomes 
available.  
 After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
75  If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a SAE paper form (see next 
section) or to t he medical monitor  by [CONTACT_756].  
 Contacts for SAE reporting can be found in site training material.  
 
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the medical monitor . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found in site training material.  
10.3.6.  Regulatory Reporting R equirements  
SAE Regulatory Reporting  
● Prompt notification by [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRB/IEC , and investigators.  
● An investigator who receives an investigator safety report describing an SAE or 
other specific safety information (for example, summar y or listing of SAEs) 
from the sponsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropriate according to local requirements.  
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
76 10.4. Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions
Word/Phrase  Definition  
WOCBP  Females are considered a WOCBP  if 
 they have had at least one cycle of menses, or  
 they have Tanner [ADDRESS_706021] development.  
 
Any amount of spotting should be considered menarche.  If Tanner Staging of 
breasts is performed as part of study procedures, please refer to the Reproductive, 
Pregnancy and Pediatrics Safety Committee Safety Guidance for Children in 
Clinical Trial regarding Tanner staging.  
Women not of 
child bearing 
potential  Females are considered women not of child bearing potential if  
 they have a congenital anomaly such as Mullerian agenesis,  
 they are infertile due to surgical sterilization, or  
 they are post -menopausal.  
 
Examples of surgical sterilization include:  hysterectomy, bilateral oophorectomy, 
tubal ligat ion. 
Post-menopausal 
state The post -menopausal state should be defined as:  
1. A woman at any age at least [ADDRESS_706022] -surgical bilateral oophorectomy 
with or without hysterectomy, confirmed by [CONTACT_31083]; or  
2. A woman at least [ADDRESS_706023] 
uterus, not on hormone therapy*, who has had cessation of menses for at 
least 12 consecutive months without an alternative medical cause, AND  
With a follicle -stimulating hormone >40 mI U/mL; or  
3. A woman [ADDRESS_706024] 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy  
 
* Women should not be taking medications during amenorrhea such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs), or chemotherapy that could 
induce transient amenorrhea.  
Reproductive 
Toxicology 
Studies  Embryo-fetal studies are toxicity studies in pregnant animals designed to identify 
abnormalities in the development of fetuses, which could indicate potential for 
teratogenicity in humans.  The relevant dosing period is during organogenesis.  
 
10.4.2.  Contraception Guidance  
Contraceptive use by [CONTACT_9281].  
 
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
77 10.5. Appendix 5: Genetics  
Use/Analysis of DNA  
● Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Variable response to 
study intervention may be due to genetic determinants that impact drug 
absorption, distribution, metabolis m, and excretion; mechanism of action of the 
drug; disease etiology; and/or molecular subtype of the disease being treated. 
Therefore, where local regulations and IRB/IEC allow, a blood sample will be 
collected for DNA analysis from consenting participants . 
● DNA samples will be used for research related to donanemab or AD and related 
diseases. They may also be used to develop tests/assays including diagnostic tests 
related to donanemab  or other amyloid targeting interventions  and AD. Genetic 
research may consist of the analysis of one or more candidate genes or the 
analysis of genetic markers throughout the genome (as appropriate).  
● DNA samples will be analyzed for pharmacogenetic research . 
● The samples may be analyzed as part of a multi -study assessment  of genetic 
factors involved in the response to donanemab  or study interventions of this class 
to understand study disease or related conditions.  
● The results of genetic analyses may be reported in the clinical study report or in a 
separate study summary.  
● The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
● The samples will be retained while research on donanemab or other amyloid 
targeting interventions  continues but no longer than 15 years  or other period as 
per local requirements.  
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
78 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  
10.6.1.  Hepatic Evaluation Testing  
See Section  8.2.[ADDRESS_706025] bilirubin  
Erythrocytes (RBCs - red blood cells)  Alkaline phosphatase (ALP)  
Leukocytes (WBCs - white blood cells)  Alanine aminotransferase (ALT)  
Differential:  Aspartate aminotransferase (AST)  
    Neutrophils, segmented  Gamma -glutamyl transferase (GGT)  
    Lymphocytes  Creatine kinase (CK)  
    Monocytes  Other Chemistry  
    Basophils  Acetaminophen  
    Eosinophils  Acetaminophen protein adducts  
Platelets  Alkaline phosphatase isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Coagulation  Copper  
Ethyl alcohol (EtOH)  
Prothrombin time, INR (PT -INR)  Haptoglobin  
Serology  Immunoglobulin IgA (quantitative)  
 Hepatitis A virus (HAV) testing:  Immunoglobulin IgG (quantitative)  
    HAV total antibody  Immunoglobulin IgM (quantitative)  
    HAV IgM antibody  Phosphatidylethanol (PEth)  
Hepatis B virus (HBV) testing:  Urine Chemistry  
    Hepatitis B surface antigen (HBsAg)  Drug screen  
    Hepatitis B surface antibody (anti -HBs)  Ethyl glucuronide (EtG)  
    Hepatitis B core total antibody (anti -HBc)  Other Serology  
    Hepatitis B core IgM antibody  Anti-nuclear antibody (ANA)  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
79     Hepatitis B core IgG antibody  Anti-smooth muscle antibody (ASMA)a 
    HBV DNAd Anti-actin antibodyb 
Hepatis C virus (HCV) testing:  Epstein -Barr virus (EBV) testing:  
    HCV antibody      EBV antibody  
    HCV RNAd     EBV DNAd 
Hepatitis D virus (HDV) testing:  Cytomegalovirus (CMV) testing:  
    HDV antibody      CMV antibody  
Hepatitis E virus (HEV) testing:      CMV DNAd 
    HEV IgG antibody  Herpes simplex virus (HSV) testing:  
    HEV IgM antibody      HSV (Type 1 and 2) antibody  
    HEV RNA d     HSV (Type 1 and 2) DNA d 
Microbiology c Liver kidney microsomal type 1 (LKM -1) antibody  
Culture:   
    Blood   
    Urine   
a Not required if anti -actin antibody is tested.  
b Not required if anti -smooth muscle antibody is tested.  
c Assayed ONLY by [CONTACT_1697] -designated local laboratory; no central testing available.  
d Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
80 10.7. Appendix 7: Flortaucipir F18 PET Imaging  
Flortaucipir F18 PET scan will be performed after eligibility is established  (Section 1.3). 
No results will be provided to site investigators, participants, and study partners for the 
flortaucipir F18 scans . Any significant findings that may be of potential medical concern will be  
provided for appropriate follow -up 
PET Scan -Specific Information  
PET Scan Procedures  
Specific imaging acquisition protocols designed to ensure consistency across sites will be 
provided in a PET Imaging Manual.  
Scan Safety  
The primary risk related to flor taucipir F18 PET is radiation exposure. Details on the amount of 
exposure estimated to occur on each imaging occasion and cumulatively are shown in the table 
below  and will be provided in the ICF . The safety profile of flortaucipir has been well -
characteri zed in clinical studies and is considered acceptable for a diagnostic 
radiopharmaceutical. Details on the clinical information to date regarding flortaucipir F18 
exposure will be provided in the ICF. More detailed information about the known and expected 
benefits and risks of flortaucipir F18 can be found in the IB.  
Participants must minimize movement during each PET procedure, which can last [ADDRESS_706026] state -of-the-art imaging systems are designed to reduce head motion 
and partici pant discomfort.  
The table below shows the effective radiation dose of the Study AAC N’s PET scans . 
 Effective 
Dose (mSv) 
per Scana Number of 
Scans in First 
Yearb Effective Dose 
(mSv) for 
Scans in First 
Year  Number of 
Scans in 
Second 
Yearb Effective Dose 
(mSv) for 
Scans in 
Second Year  Sum of 
Effective 
Dose (mSv) 
for Years 1 
and 2  
Flortaucipir 
F18 Scan 
(10 mCi IV)  9.10 1 9.10 0 0 9.10 
Florbetapir 
F18 Scan 
(10 mCi IV)  7.43 2 14.86  2 14.86  29.72  
Totals   3 23.96  2 14.86  38.82  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
81 Abbreviations:  CT = computerized tomography; ED = early discontinuation; IV = intravenous infusion; 
PET = positron emission tomography.  
a Dose shown includes radiation exposure from the radiotracer and assumes a nonclinical CT scan is obtained 
(estimated at 0.4 mSv) as part of the PET scan attenuation correction process when the scan is done on a PET/CT 
scanner. A clinical CT scan is not needed during the PET scan session and, because it will add additional 
radiation exposure, it is not recommended.  
b In the event of an ED scan, up to 1 additional florbetapir F18 scan may be received in 1 year.  
Note:  In the event a repeat scan is required (for example, the scan is not analyzable), 1 additional flortaucipir F18 
and/or 1 additional florbetapir F18 scan may be received in 1  year.  
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
82 10.8. Appendix 8:  Florbetapir F18 PET Imaging  
Florbetapir F18 PET scans will be performed as part of the study eligibility criteria to determine 
participant eligibility for participation in Study AAC N. Additional florbe tapir F18 PET scans 
will be performed as indicated in the SoA (Section 1.3). 
Site investigators, participants, and study partners will not be inform ed of the results of PET 
scans obtained following randomization as they relate to the study. Any findings that may be of 
potential medical concern will be provided for appropriate follow -up. 
PET Scan -Specific Information  
PET Scan Procedures  
Specific imaging acquisition protocols designed to ensure consistency across sites will be 
provided in a PET Imaging Manual.  
PET Scan Safety  
The primary risk related to florbetapir F18 PET is radiation exposure. Details on the amount of 
exposure estimated to occur on each imaging occasion and cumulatively are presented in the 
table in Appendix 7 and will be provided in the ICF . Details on the clinical information to date 
regarding florbetapir F18 exposure will be provided in the ICF. More detailed information about 
the known and expected benefits and risks of florbetapir F18 can be found in the [LOCATION_002] 
Package Insert for florbetapir F18 Injection (AmyvidTM package insert, 2012).  
Participants must minimize movement during each PET procedure, which can last [ADDRESS_706027] state -of-the-art imaging systems are designed to reduce head motion 
and participant discomfort.  
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
83 10.9. Appendix 9:  CDR and MMSE  
10.9.1.  CDR  
The CDR -SB (Hughes et al. 1982; Morris 1993) is a global assessment tool t hat can be used to 
effectively evaluate both cognition and function. The tool was initially developed to measure 
dementia severity and covers 6 categories or “boxes”: Memory, Orientation, Judgment and 
Problem Solving, Community Affairs, Home and Hobbies, a nd Personal Care. The CDR global 
ratings, calculated using an algorithm, range from 0 (no dementia) to 3 (severe dementia) while 
CDR -SB scores, calculated by [CONTACT_541465], range from 0 to 18 (with higher scores 
indicative of more impairment). Scor ing is determined by a clinician through a semistructured 
and in -depth interview with both the affected individual and their study partner. The study 
partner and participant must be interviewed separately. This scale demonstrates acceptable 
psychometric ch aracteristics (Coley et al. 2011; Cedarbaum et al. 2013) and has been shown to 
be sensitive enough to detect disease progression, even in populations with less advanced clinical 
disease (Williams et al. 2013; Wessels et al. 2015).  
10.9.2.  MMSE  
The MMSE is a brief instrument used to assess cognitive function in patients (Folstein et al. 
1975). The instrument measures orientation, memory, and attention; the ability of the participant 
to name [CONTACT_272755]; follow verbal and written commands; write a s entence; and copy figures. The 
range for the total MMSE score is 0 to 30, with lower scores indicating greater level of 
impairment.  
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
84 10.10.  Appendix 10: Abbreviations and Definitions  
Term  Definition  
Aβ Amyloid beta  
AChEI  acetylcholinesterase inhibitor  
AD Alzheimer’s disease  
ADA  Anti-drug antibody  
AE Adverse event  
ALP Alkaline phosphatase  
ALT alanine aminotransferase  
ApoE  Apolipoprotein E  
ARIA  Amyloid -related imaging abnormalities  
AST aspartate aminotransferase  
C-CASA  Columbia Classification Algorithm of Suicide Assessment  
CDR  Clinical Dementia Rating  
CDR -SB CDR -Sum of Boxes  
CFR Code of Federal Regulations  
CI Confidence interval  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CK Creatine kinase  
COA  clinical outcome assessment  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF case report form; a printed, optical, or electronic document designed to record all of the 
protocol -required information to be reported to th e sponsor for each trial participant.  
cSS cortical superficial siderosis  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CT computed tomography  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
[ADDRESS_706028] 
(DMB) is a group of independent scientists who are appointed to monitor the safety and 
scientific integrity of a human research intervention, and to make recommendations to 
the sponsor regard ing the stoppi[INVESTIGATOR_31081] a study for efficacy, or for harms, or for futility. 
The composition of the committee is dependent upon the scientific skills and 
knowledge required for monitoring the particular study.  
ECG  Electrocardiogram  
EDC  Electronic data capture  
enroll  The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.  
enter  Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
EU European Union  
FDA Food and Drug Administration  
GCP  good clinical practice  
GGT  Gamma -glutamyl transferase  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IgG Immunoglobulin G  
informed consent  A process by [CONTACT_9444] a participant voluntarily confirms their willingness to participate in 
a particular study, after having been informed of all aspects of the study tha t are 
relevant to the participant’s decision to participate. Informed consent is documented by 
[CONTACT_3553] a written, signed and dated informed consent form . 
INR international normalized ratio  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthoriz ed indication, or marketed products used to 
gain further information about the authorized form.  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
[ADDRESS_706029]  
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a participant (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that participant allocated to a treatment group should be followed u p, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.  
IV intravenous  
IWRS  interactive web -response system  
MCI Mild cognitive impairment  
MMSE  Mini -Mental State Examination  
MRI Magnetic resonance imaging  
NIMH  National Institute of Mental Health  
participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PD pharmacodynamics  
PET positron emission tomography  
PI [INVESTIGATOR_541433]-INR Prothrombin time – INR 
Q2W  Every 2 weeks  
Q4W  Every 4 weeks  
QTc corrected QT interval  
QTcF  QT interval corrected using Fridericia’s formula  
QTL Quality tolerance limit  
SAC  Statistical Analysis Center  
SAE serious adverse event  
SAP statistical analysis plan  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
[ADDRESS_706030] Upper limit of normal  
US [LOCATION_002]  
USPI  [INVESTIGATOR_541434] I5T-MC-AACN (b) 
88 10.11.  Appendix 1 1: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amen dment is located 
directly before the Table of Contents (TOC).  
Amendment a: (11-Oct-2021 ) 
 
Overall Rationale for the Amendment:  
This amendment allows for  better characterization of the incidence and severity of ARIA at an 
earlier time point.  
 
Section # and 
Name  [CONTACT_11029]  
1.3. Schedule of 
Activities  Modified “Weeks relative to 
randomization  first infusion ”. Clarification. Visits  should be scheduled 
in relation to the first IP infusion.  
  Changed V3 interval tolerance  
from “±7” days to “ 7 to +10” 
days.  To provide additional time to perform and 
review MRI prior to infusion.  
 Added line to collect weight 
for aducanumab participan ts. Aducanumab uses weight -based dosing. 
Weight is not recorded in the CRF.  
 Added MRI at V3. Added text 
to the Comment s field about 
MRI at V3, including text 
about MRI timings relative to 
the first and fourth infusions.  To allow for better characterization of the 
incidence and severity of ARIA at an 
earlier time point.  
6.5. Dose 
Modification  Modified description of 
ARIA events in relation to 
dose modification and 
providing data for the ARIA 
Related Events CRF.  Clarification.  
6.8.1. Medicat ions 
for Alzheimer’s 
Disease  Added “When medically 
indicated, initiation, increase , 
or discontinuation of 
symptomatic treatments for 
AD is permitted.”  Clarification.  
7.1.3. Amyloid -
Related Imaging 
Abnormalities 
(ARIA)  Added note “While most 
cases of ARIA -E are 
asymptomatic, serious cases 
have been reported. Available 
data suggest serious cases are 
most likely to occur early in To provide additional information.  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
89 Section # and 
Name  [CONTACT_541468], after the first, second, 
or third infusion.”  
 Added cross -references to the 
Manual of Operations 
regarding information about 
temporary and permanent 
discontinuation guidance.  To provide further guidance.  
 Modified text regarding 
considerations related to 
reinitiating study 
intervention. . Recommendati on of DMC . 
 Added instructions to 
complete the ARIA Related 
Events CRF in the event of 
symptomatic ARIA -H. To provide instructions.  
8.2.5. Magnetic 
Resonance 
Imaging  Added text to allow 
performance of unscheduled 
MRIs . Clarification.  
 
  
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
90 11. References  
Aducanumab -avwa package insert. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf . Published on: 
Jun 2021. Accessed on 2 1 Jul 2021. 
AmyvidTM [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012.  
Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand 
Suppl . 1996;165:3 -12. https://doi.org/ 10.1111/j.[ADDRESS_706031] procedures. Stat Med . 2009;28(4):586 -604. https://doi.org/ 10.1002/sim.3495.  
Bretz F, Posch M, Glimm E, et al. Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests. Biom J . 2011;53(6):89 4-913. 
https://doi.org/ 10.1002/bimj.201000239.  
Cedarbaum JM, Jaros M, Hernandez C, et al. ; Alzheimer's Disease Neuroimaging Initiative. 
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome 
measure for Alzheimer's disease cli nical trials. Alzheimers Dement.  2013;9([ADDRESS_706032]):S45 -S55. 
https://doi.org/ 10.1016/j.jalz.2011.11.002.  
Coley N, Andrieu S, Jaros M, et al. Suitability of the Clinical Dementia Rating -Sum of Boxes as 
a single primary endpoint for Alzheimer's disease trials.  Alzheimers Dement . 2011;7(6):602 -
610.e2.  https://doi.org/ 10.1016/j.jalz.2011.01.005.  
[CUIMC] Columbia University Irving Medical Center. Columbia -Suicide Severity Rating Scale 
(C-SSRS). The Columbia Lighthouse Project web site. Available at: www.cssrs.col umbia.edu. 
Accessed 9 March 2019.  
Doody RS, Thomas RG, Farlow M, et al. ; Alzheimer’s Disease Cooperative Study Steering 
Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild -to-moderate 
Alzheimer's disease. N Engl J Med . 2014;370(4):311 -321. https://doi.org/ 
10.1056/NEJMoa1312889.  
Doraiswamy PM, Sperling RA, Coleman RE,  et al. ; AV45 -A11 Study Group. Amyloid -β 
assessed by [CONTACT_389754] F 18 PET and 18 -month cognitive decline: a multicenter study. 
Neurology . 2012;79(16):1636 -1644. https://doi.org/ 10.1212/WNL.0b013e3182661f74.  
Ferrero J, Williams L, Stella H, et al. First -in-human, double -blind, placebo -controlled, single -
dose escalation study of aducanumab (BIIB037) in mild -to-moderate Alzheimer's disease. 
Alzheimers Dement (N  Y). 2016 Jun 20;2(3):169 -176. https://doi.org/ 
10.1016/j.trci.2016.06.002.  
Fleisher AS, Chen K, Quiroz YT,  et al. Associations between biomarkers and age in the 
presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross -sectional study. 
JAM A Neurol . 2015;72(3):316 -324. https://doi.org/ 10.1001/jamaneurol.2014.3314.  
Folstein MF, Folstein SE, McHugh PR. “Mini -mental state”. A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res . 1975;12(3):189 -198. 
https://doi.org/ 10.1016/0022 -3956(75)[ZIP_CODE] -6. 
CONFIDENTIAL  Protocol number I5T-MC-AACN (b) 
91 Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J 
Psychiatry . 1982;140:566 -572. https://doi.org/ 10.1192/bjp.140.6.566.  
Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the 
Alzheimer's pathological cascade. Lancet Neurol . 2010;9(1):119 -28. https:// doi.org/ 
10.1016/S1474 -4422(09)[ADDRESS_706033] Alzheimer's di sease 
and age -related cognitive decline. Nature . 2012;488(7409):96 -99. https://doi.org/ 
10.1038/nature11283.  
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. N Engl J 
Med. 2021 May 6;384(18):1691 -1704. https:// doi.org/  10.1056/NEJMoa2100708. Epub 2021 
Mar 13.  
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology . 
1993;43(11):2412 -2414.  https://doi.org/ 10.1212/wnl.43.11.2412 -a. 
Sampson HA, Munoz -Furlong A, Campbell RL, et al. Second symp osium on the definition and 
management of anaphylaxis: summary report —Second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin 
Immunol.  2006;117(2):391 -7. https://doi.org/ 10.1016/j.jaci.200 5.12.1303.  
Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA . 2000;283(12):1615 -1617. 
https://doi.org/ 10.1001/jama.283.12.1615.  
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in 
Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50 -6. https://doi.org/  
10.1038/nature19323. Update in: Nature . 2017;546(7659):564. https://doi.org/ 
10.1038/nature22809 . 
Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in 
mild Alzheimer's disease patients. Alzheimers Dement . 2016;12(2):110 -120. https://doi.org/ 
10.1016/j.jalz.2015.06.1893.  
Wessels AM, Siemers ER, Yu P, et al. A combined measure of cognition and function for 
clinical trials: the integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alzheimers 
Dis. 2015;2(4):227 -241. https://doi.org/ 10.[ZIP_CODE]/jpad.2015.82.  
Williams MM, Storandt M, Roe CM, Morris JC. Progression of Alzheimer's disease as measured 
by [CONTACT_541466]. Alzheimers Dement.  
2013;9([ADDRESS_706034]):S39 -S44. https://doi.org/ 10.1016/j.jalz.2012.01.005.  
Signature [CONTACT_11032]-CLIN-059456 v1.0
Signature [CONTACT_11032]-CLIN-059456 v1.0Approval
17-May-2022 12:41:26 GMT[PHONE_006]
Approval
17-May-2022 16:07:39 GMT[PHONE_006]
Approved on 17 May 2022 GMT
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]